



04/07/99

Docket No. 58463/JPW/EMW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Honorable Assistant Commissioner for Patents
 Washington, D.C. 20231
 Box: Patent Application
 S I R:

April 7, 1999

jc640 U.S. PTO

09/287884



04/07/99

Transmitted herewith for filing are the specification and claims of the patent application of:

Harold J. Wanebo and Shashikant Mehta

for

Inventor(s)

COMBINATIONS OF CERAMIDE AND CHEMOTHERAPEUTIC AGENTS FOR INDUCING CELL DEATH AND
 USES THEREOF IN TREATING CANCER

Title of Invention

Also enclosed are:

X 17 sheet(s) of informal X formal drawings.

 Oath or declaration of Applicant(s).

 A power of attorney

 An assignment of the invention to

 A Preliminary Amendment

X A verified statement to establish small entity status under 37 C.F.R. §1.9 and §1.27.

The filing fee is calculated as follows:

CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT

	NUMBER FILED		NUMBER EXTRA*		RATE		FEE	
					SMALL ENTITY	OTHER ENTITY	SMALL ENTITY	OTHER ENTITY
Total Claims	22 -20	=	2	X	\$ 9.00	\$18.00	= \$ 18.00	\$
Independent Claims	4 -3	=	1	X	\$39.00	\$78.00	= \$ 39.00	\$
Multiple Dependent Claims Presented: <u> X </u> Yes <u> </u> No					\$130.00	\$260.00	= \$ 130.00	\$

*If the different in Col. 1 is
 less than zero, enter "0" in
 Col. 2

BASIC FEE	\$ 380	\$ 760
TOTAL FEE	\$ 567.00	\$

April 7, 1999

Letter of Transmittal
Page 2

☒ A check in the amount of \$ 567.00 to cover the filing fee.

☐ Please charge Deposit Account No. _____ in the amount of \$ _____.

☒ The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the following or credit any over-payment to Account No. 03-3125:

☒ Filing fees under 37 C.F.R. §1.16.

☒ Patent application processing fees under 37 C.F.R. §1.17.

☐ The issue fee set in 37 C.F.R. §1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. §1.311(b).

☒ Three copies of this sheet are enclosed.

☐ A certified copy of previously filed foreign application No. _____
_____ filed in _____ on _____.
Applicant(s) hereby claim priority based upon this aforementioned
foreign application under 35 U.S.C. §119.

☒ Other (identify) Express Mail Certificate of Mailing bearing label No.
EJ 470 126 162 US dated April 7, 1999 and a loose
set of formal figures.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

Applicant or Patentee: Harold J. Wanebo and Shashikant Mehta Attorney's
Serial or Patent No.: _____ Docket No: 58463/JPW/EMW
Filed or Issued: _____
Title of Invention or Patent: COMBINATIONS OF CERAMIDE AND CHEMOTHERAPEUTIC
AGENTS FOR INDUCING CELL DEATH AND USES THEREOF
IN TREATING CANCER

VERIFIED STATEMENT (DECLARATION) CLAIMING
SMALL ENTITY STATUS UNDER 37 C.F.R. §1.9(f)
AND §1.27(d) - NONPROFIT ORGANIZATION

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

Name of Organization: Roger Williams Hospital

Address of Organization: 825 Chalkstone Avenue
Providence, Rhode Island 02908

TYPE OF ORGANIZATION:

☐ UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION
☒ TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE 26 U.S.C. §§501(a) and 501(c)(3)
☐ NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA
NAME OF STATE: _____
CITATION OF STATUTE: _____
☐ WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE 26 U.S.C. §§501(a) and 501(c)(3) IF LOCATED IN THE UNITED STATES OF AMERICA
☐ WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA IF LOCATED IN THE UNITED STATES OF AMERICA
NAME OF STATE: _____
CITATION OF STATUTE: _____

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 C.F.R. §1.9(e)* for purposes of paying reduced fees under 35 U.S.C. §41(a) and 41(b), with regard to the invention entitled COMBINATIONS OF CERAMIDE AND CHEMOTHERAPEUTIC AGENTS FOR INDUCING CELL DEATH AND USES THEREOF IN TREATING CANCER

by inventor(s) Harold J. Wanebo and Shashikant Metha

described in:

☒ the specification filed herewith
☐ application serial no. _____ filed _____
☐ patent no. _____ issued _____

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above identified invention.

If the rights held by the nonprofit organization are not exclusive each individual, concern, or organization known to have rights to the invention is listed below^a and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 C.F.R. §1.9(d)* or a nonprofit organization under 37 C.F.R. 1.9(e)*

^a NOTE: Separate verified statements are required from each person, concern, or organization having rights to the invention averring to their status as small entities, 37 C.F.R. §1.27.

Name: N/A

Address: _____

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. 37 C.F.R. §1.28(b)*.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

0990040-49343260
Name of Person Signing: Thomas L. Slowey
Title In Organization: Chief Financial Officer
Address: Roger Williams Hospital
825 Chalkstone Avenue, Providence, Rhode Island 02908
Signature: Thomas L. Slowey
Date Of Signature: 3/24/85

**Application
for
United States Letters Patent**

652040-48828260

To all whom it may concern:

Be it known that We, Harold J. Wanebo and Shashikant Mehta

have invented certain new and useful improvements in

COMBINATIONS OF CERAMIDE AND CHEMOTHERAPEUTIC AGENTS FOR INDUCING CELL
DEATH AND USES THEREOF IN TREATING CANCER

of which the following is a full, clear and exact description.

COMBINATIONS OF CERAMIDE AND CHEMOTHERAPEUTIC AGENTS FOR
INDUCING CELL DEATH AND USES THEREOF IN TREATING CANCER

5 Throughout this application, various references are
referred to within parentheses. Disclosures of these
publications in their entireties are hereby incorporated
10 by reference into this application to more fully describe
the state of the art to which this invention pertains.
Full bibliographic citation for these references may be
found at the end of this application, preceding the
claims.

15 BACKGROUND OF THE INVENTION

Paclitaxel, an alkaloid compound originally derived from
the bark of the Pacific yew tree, is currently used in
treatment of breast and ovarian as well as many other
20 types of cancer, including non-small cell lung carcinoma,
prostate, head and neck cancer, and lymphoma.(1-9) The
main site of paclitaxel's action is the microtubules of
eukaryotic cells, whose functions include formation of
the mitotic spindle during cytokinesis, intracellular
25 transport, shape maintenance, cell motility and
attachment, and regulation of transmembrane signals from
cell-surface receptors.(10) Paclitaxel acts predominantly
by promoting the polymerization of tubulin subunits into
microtubules and by preventing depolymerization of the
30 microtubules once they are formed.(11) Paclitaxel has
been shown to block cell growth in the G₂-M phase of the
cell cycle, with subsequent inhibition of mitosis.(12,13)
Changes in the structure of microtubules and the mitotic
spindle apparatus lead not only to inhibition of cellular
35 division and migration of chromosomes but also to
chromosomal breakage. (14)

Sphingomyelin, a cell membrane component, can be
hydrolyzed to ceramide and phosphorylcholine by acid or

neutral sphingomyelinase.(15,16) This hydrolysis event initiates an intracellular signalling cascade associated with the stimulation of numerous biological activities, including induction of apoptosis(17-24) and arrest of cell growth in the G_0 - G_1 phase.(25-27)

The rationale for combination of paclitaxel and ceramide is based on previous studies that demonstrated activation of Fas expression on leukemic cells by another chemotherapeutic agent, vincristine, which acts primarily by destroying the mitotic spindle in the G_2 -M phase.(28-30) Since ceramide has been reported to mediate, in part, Fas activation,(15,22,23) two agents that appear to converge on some common point in the sphingomyelin/ceramide pathway was evaluated.

Moreover, since these agents act in different phases of the cell cycle, and not all tumor cells can be arrested and/or eliminated in the G_2 -M phase by paclitaxel exposure, additional anti-cancer agents may be needed in the therapeutic regimen. This is supported by the observation that paclitaxel combined with other chemotherapeutic agents in treatment of a variety of cancers, including leukemia, typically produces a stronger tumor cell growth inhibition than a single chemotherapeutic agent.(31-33) Therefore the experiments combine ceramide, a reported G_0 - G_1 blocker, with paclitaxel to prevent proliferation of cells that escape the G_2 -M arrest induced by paclitaxel.

This invention provides a method of combination therapy wherein paclitaxel (or other chemotherapeutic agents) and ceramide interact synergistically to induce cytotoxicity and apoptosis in carcinoma cells thereby decreasing the growth of cancer cells.

SUMMARY OF THE INVENTION

This invention provides a method for increasing apoptosis in tumor cells comprising contacting the tumor cells with: a) an effective amount of at least one antitumor chemotherapeutic agent and b) an effective amount of a ceramide, sequentially or concomitantly, wherein the apoptosis induced by the combination of the antitumor chemotherapeutic agent and the ceramide is greater than the apoptosis induced by contact of the tumor cells with either the antitumor chemotherapeutic agent alone or the ceramide alone, thereby increasing apoptosis in tumor cells.

This invention also provides a method of decreasing a size of a tumor comprising contacting the tumor with: a) an effective amount of at least one antitumor chemotherapeutic agent and b) an effective amount of a ceramide, sequentially or concomitantly, wherein the induced decrease in size of the tumor is greater than the decrease in size of a tumor after contacting the tumor with either the antitumor chemotherapeutic agent alone or the ceramide alone, thereby decreasing the size of the tumor.

This invention further provides a method of treating cancer in a subject which comprises the method according to either of the above-described methods of increasing apoptosis in tumor cells or the above-described of method decreasing a size of a tumor in the subject.

This invention provides a pharmaceutical composition comprising at least one antitumor chemotherapeutic agent in an amount effective to induce apoptosis of tumor cells and at least one ceramide in an amount effective to induce apoptosis of tumor cells and a pharmaceutically acceptable carrier.

5 This invention provides a method for treating cancer in
a subject comprising administering to the subject an
effective amount of at least one antitumor
chemotherapeutic agent and an effective amount of at
least one ceramide, sequentially or concomitantly.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1. Effect of paclitaxel (taxol) and ceramide on Jurkat cell growth inhibition. Jurkat cells were maintained as described in Materials and Methods, resuspended at a density of 1×10^6 cells/ml, washed by centrifugation for 5 minutes at 1500 rpm, and plated in a final volume of 0.2 ml per well in complete RPMI 1640 medium containing 0% to 10% fetal bovine serum. Paclitaxel (0 to 60 ng/ml and ceramide (0 to 50 μ g/ml) were added to Jurkat cells either alone or in combination, and proliferation was measured in cpm using a 3-day ^3H thymidine uptake assay. The data are normalized to respective cell control.

Figure 2. Effects of Serum on Paclitaxel and Ceramide Induced Jurkat Cell Growth Inhibition. The combined effect of the addition of paclitaxel (0.6 ng/ml) and ceramide (25 μ g/ml) on Jurkat cell growth in 0% to 10% fetal bovine serum is shown. Jurkat cells were maintained and treated as described in Materials and Methods. Cell growth was assessed by a ^3H -thymidine incorporation assay as described in Materials and Methods.

Figure 3A-3F. Cell-cycle analysis of Jurkat cells in the presence of paclitaxel and/or ceramide. Cell-cycle analysis was performed at 24 hours because, by 48 and 72 hours, most of the cells (treated with a combination of paclitaxel and ceramide) were hypodiploid, and accurate assessment of the percentage of cells in G_0 - G_1 , S- and G_2 -M phases could not be made. Propidium iodide (0.05 mg/ml) was added to cell cultures in a total volume of 0.5 ml. Samples were analyzed by FACScan (Becton Dickinson, Costa Mesa, CA). Cell-cycle distribution was calculated as a percentage of the total population of both live and hypodiploid cells. (**Figure 3A**) Untreated Jurkat control cells with no additions of paclitaxel or

ceramide; (Figure 3B) with addition of 25 $\mu\text{g/ml}$ of
ceramide; (Figure 3C) with 0.6 ng/ml of paclitaxel;
(Figure 3D) with 0.6 ng/ml of paclitaxel and 25 $\mu\text{g/ml}$ of
ceramide combined; (Figure 3E) with 6.0 ng/ml of
paclitaxel; and (Figure 3F) with 6.0 ng/ml of paclitaxel
and 25 $\mu\text{g/ml}$ ceramide combined.

Figures 4A-4F. Wright's stain analysis of Jurkat cells
treated with paclitaxel and ceramide. Morphology of
paclitaxel- and ceramide-induced apoptosis in Jurkat cells
stained with Giemsa/Wright at 48 hours. (Fig. 4A)
Untreated Jurkat control cells with no additions of
paclitaxel or ceramide; (Fig. 4B) with 25 $\mu\text{g/ml}$ of
ceramide; (Fig. 4C) with 0.6 ng/ml of paclitaxel; (Fig.
4D) with 6.0 ng/ml of paclitaxel; (Fig. 4E) with 0.6
ng/ml of paclitaxel and 25 $\mu\text{g/ml}$ of ceramide combined;
and (Fig. 4F) with 6.0 ng/ml of paclitaxel and 25 $\mu\text{g/ml}$
of ceramide combined.

Figure 5A-5H. TUNEL assay for the measurement of
paclitaxel- and ceramide-induced Jurkat cell apoptosis.
TUNEL assay was performed at both 24 (panel A) and 48
(panel B) hours. Apoptotic cells are demonstrated by the
area M1. Fig. 5A and 5E represent untreated control
cells; Figs. 5B and 5F represent cells treated with 25
 $\mu\text{g/ml}$ ceramide; Fig. 5C and 5G represent cells treated
with 0.6 ng/ml paclitaxel; and Figs. 5D and 5H represent
cells treated with both ceramide and paclitaxel. The
percentage of apoptotic cells obtained by flow cytometric
analysis is shown below each figure.

Figures 6A-6B. Effect of Paclitaxel (Taxol) and Ceramide
on the growth of Tu138 cells. Tu138 cells ($2 \times 10^4/\text{well}$)
were plated in 96-well culture plates in the presence and
absence of paclitaxel (Taxol) or ceramide for a period of
3 days and then subjected to MTT dye assay as indicated
in Materials and Methods. The x-axis represents

concentrations of paclitaxel (Taxol) (0-6000 ng/ml; **Fig. 6A**) and ceramide (0-50 μ g/ml; **Fig. 6B**) and the y-axis represents optical density (540 nm) of live cells that incorporated MTT dye. Each data point represents an average and a standard deviation of triplicate determinations.

Figure 7. Time Kinetics of the Combined Action of Paclitaxel (Taxol) and Ceramide. Tu138 cells were cultured as indicated in the **Figure 6** legend in the presence and absence of paclitaxel (Taxol) (600 ng/ml) and/or ceramide (25 μ g/ml). The x-axis represents optical density of incorporated dye and y-axis represents the time of measurements at 24, 48 and 72 hours.

Figure 8. ED_{50} Isobologram Analysis of Synergistic Action of Paclitaxel (Taxol) and Ceramide. For the construction of isobologram, ED_{50} were determined individually from seven independent experiments performed at various dilutions of paclitaxel and ceramide by best fit analysis. Also, a line plot was generated by calculations of ED_{10} through ED_{50} values for both paclitaxel and ceramide. The x-axis represents paclitaxel (Taxol) concentrations necessary to generate ED_{50} in combination with ceramide concentrations plotted on the y-axis. The scatter plot is the result of calculated ED_{50} values from seven independent experiments representing combined exposures of paclitaxel and ceramide.

Figure 9: Paclitaxel (Taxol) and Ceramide Induced Cell Cycle Progression and Flow Cytometry Analysis of Tu138 cells. Tu138 cells at a density of 0.5×10^6 /ml were cultured in the presence and absence of paclitaxel (Taxol) (600 ng/ml) and/or ceramide (25 μ g/ml) for 24 (panel A) and 48 (panel B) hours in either 6-well culture plates to T-25 flasks. At the end of the incubation period, cells were trypsinized, washed and subjected to a flow cytometric analysis as described in Materials and

Methods. The x-axis of the scans represents DNA content and y-axis represents the number of cells. The analysis of the acquired samples with the use of "Modfit" software is shown underneath each treatment as the percent population of viable cells in various phases of the cell cycle.

Figure 10. TUNEL Assay for the Measurements of Paclitaxel (Taxol) and Ceramide Induced Apoptosis of Tu138 cells. For the measurement of apoptosis, Tu138 cells were cultured with or without paclitaxel (Taxol) (600 ng/ml) and/or ceramide (25 μ g/ml) as described **Figure 9**. The analyses of acquired samples were based on an antibody binding to DNA fragments shown as fluorescence on x-axis and cell count on y-axis. For the positive control, Tu138 cells were treated with DNase for 10 minutes at room temperature prior to the acquisition on FACScan. The percent shown underneath each scan was obtained by the use of CELL Quest software (Becton Dickinson, CA) and is represented by M1.

Figure 11. Growth of Human Squamous Carcinoma Cells in Nude Mice. Tumor growth of head and neck squamous carcinoma (TU138) was significantly reduced by treatment with a combination of paclitaxel and ceramide.

Figure 12. Excised Tumor Weights in Nude Mice. Tumor growth of head and neck squamous carcinoma (TU138) was significantly reduced by treatment with a combination of paclitaxel and ceramide compared with tumor growth reduction in control, nude mice treated with paclitaxel alone, and nude mice treated with ceramide alone.

DETAILED DESCRIPTION OF THE INVENTION

This invention provides a method for increasing apoptosis in tumor cells comprising contacting the tumor cells with: a) an effective amount of at least one antitumor chemotherapeutic agent and b) an effective amount of a ceramide, sequentially or concomitantly, wherein the apoptosis induced by the combination of the antitumor chemotherapeutic agent and the ceramide is greater than the apoptosis induced by contact of the tumor cells with either the antitumor chemotherapeutic agent alone or the ceramide alone, thereby increasing apoptosis in tumor cells.

As used herein "increasing apoptosis" is defined as an increase in the rate of programmed cell death, i.e. more cells are induced into the death process as compared to exposure (contact with) either the chemotherapeutic agent alone or the ceramide alone. Increasing apoptosis also includes the inhibition of cell division which results in a decrease in the total number of viable tumor cells.

As used herein "contacting tumor cells" is defined as exposing the tumor cells to combination therapy, i.e. administering to the tumor cells directly or indirectly, chemotherapeutic agent(s) and ceramide by local, regional or syatemic means.

As used herein a "ceramide" is any N-acylsphingosine. Ceramides include sphingolipids in which the sphingosine is acylated with a fatty acid acyl CoA derivative to form an N-acylsphingosine. Ceramide may be either naturally occurring or chemically synthesized. Preferably, the carbon chain length is less than 18 carbons. Examples include C6-ceramide (N-hexanoyl-D-sphingosine), C2-ceramide (N-acetyl-D-sphingosine), C8-ceramide (N-octyl-D-sphingosine) and C16-ceramide (N-palmitoyl-D-sphingosine. Other ceramides are known to one of skill

in the art.

Preferably, the ceramide (which is lipid soluble) is water soluble or made water soluble to enable contact with the tumor cells in a subject. Ceramide (6%) may be solubilized initially in alcohol and then subsequently diluted in saline or a cremophore.

This invention also provides a method of decreasing a size of a tumor comprising contacting the tumor with: a) an effective amount of at least one antitumor chemotherapeutic agent and b) an effective amount of a ceramide, sequentially or concomitantly, wherein the induced decrease in size of the tumor is greater than the decrease in size of a tumor after contacting the tumor with either the antitumor chemotherapeutic agent alone or the ceramide alone, thereby decreasing the size of the tumor.

As used herein "decreasing the size of a tumor" is defined as a reduction in the size of a tumor; the reduction is accomplished by reducing the number of proliferating tumor cells in the tumor, i.e. reducing cell division of the tumor cells, and by inducing cytotoxicity or cell death (apoptosis) of existing tumor cells. Accordingly, tumor growth is arrested or prevented.

In an embodiment of either the above-described method of increasing apoptosis in tumor cells or the above-described method of decreasing a size of a tumor via combination therapy with a chemotherapeutic agent (e.g. paclitaxel) and ceramide, the tumor cells may be or the tumor is composed of cancer cells selected from the group consisting of, but not limited to, leukemic cells, prostate cancer cells, pancreatic cancer cells and squamous cell carcinoma cells, breast carcinoma cells, melanoma cells, basal cell carcinoma cells, neuroblastoma

cells, glioblastoma multiforme cells, myeloid leukemic cells, colon carcinoma cells, endometrial carcinoma cells, lung carcinoma cells, ovarian carcinoma cells, cervical carcinoma cells, osteosarcoma cells and lymphoma cells. In further embodiments of the above-described methods, the ceramide may be a C2-ceramide, C6-ceramide, C8-ceramide, C16-ceramide, or a higher order of ceramides.

In another embodiment of either the above-described method of increasing apoptosis in tumor cells or the above-described method of decreasing a size of a tumor, the tumor cells are or the tumor is contacted first with at least one antitumor chemotherapeutic agent (e.g. paclitaxel) and subsequently contacted with the ceramide.

This invention further provides a method of treating cancer in a subject which comprises the method according to either of the above-described methods of increasing apoptosis in tumor cells or the above-described method of decreasing a size of a tumor in the subject, wherein the tumor cells or the tumor are present in the subject.

In an embodiment of the method of treating cancer in a subject according to any of the above-described methods, wherein the ceramide may be a C2-ceramide, C6-ceramide, C8-ceramide, C16-ceramide or a higher order of ceramide. In further embodiments more than one ceramide may be administered to the subject.

In another embodiment of either the above-described method of increasing apoptosis in tumor cells or the above-described method of decreasing a size of a tumor via combination therapy with a chemotherapeutic agent (e.g. paclitaxel) and ceramide, the antitumor chemotherapeutic agent is paclitaxel or compounds structurally related to the paclitaxel family of compounds, e.g. alkaloids. The antitumor chemotherapeutic

agent in any of the above-described methods may also include but not be limited to chemotherapeutic agents such as doxorubicin, cis-platin, cyclophosphamide, etoposide, vinorelbine, vinblastin, tamoxifen, colchicin, 2-methoxyestradiol. In further embodiments of the above-described methods the paclitaxel may be used together with another antitumor chemotherapeutic; combinations of any of the above-listed antitumor chemotherapeutic agents may be used.

In still further embodiments of either the above-described method of increasing apoptosis in tumor cells or the above-described method of decreasing a size of a tumor via combination therapy with a chemotherapeutic agent (e.g. paclitaxel) and ceramide, the contacting with the antitumor chemotherapeutic agent (exposure of the tumor cells to the antitumor chemotherapeutic agent) is effected by cremophore delivery or by liposome-mediated delivery and the contacting with (exposure to) the ceramide is effected by alcohol-mediated delivery or liposome-mediated delivery.

As used herein a "cremophore" is a solvent that permits solubilization of a drug or compound. Various cremophores are well known to one of skill in the art, including but not limited to oil based solvents.

In still further embodiments of any of the above-described methods of combination therapy, the route of administration (contacting the tumor cells) effected by cremophore-mediated delivery, alcohol-mediated delivery or liposome-mediated delivery of the ceramide(s) or of the antitumor chemotherapeutic agent(s) may be selected from but not limited to any of the following routes of administration: intravenous, intraperitoneal, intrathecal, intralymphatic, intramuscular, intralesional, parenteral, epidural, or subcutaneous administration; by infusion, by aerosol delivery; or by topical, oral,

nasal, anal, ocular or otic delivery.

This invention also provides a pharmaceutical composition comprising at least one antitumor chemotherapeutic agent in an amount effective to induce apoptosis of tumor cells and at least one ceramide in an amount effective to induce apoptosis of tumor cells and a pharmaceutically acceptable carrier.

This invention provides a method for treating cancer in a subject comprising administering to the subject an effective amount of at least one antitumor chemotherapeutic agent and an effective amount of at least one ceramide, sequentially or concomitantly.

As used herein an "effective amount" is defined as an amount of antitumor chemotherapeutic agent and the ceramide which provides the maximum apoptosis of tumor cells at the least toxicity to nontumor cells. The effective amount may be measured as the concentration of antitumor chemotherapeutic agent and ceramide which induces a 50% death rate (ED 50) of tumor cells.

In an embodiment of the above-described method for treating cancer in a subject, at least one antitumor chemotherapeutic agent and subsequently at least one ceramide is administered to the subject.

In another embodiment of the above-described method for treating cancer in a subject, at least one ceramide and subsequently at least one antitumor chemotherapeutic agent is administered to the subject.

In a further embodiment of the above-described method for treating cancer in a subject, the antitumor chemotherapeutic agent is paclitaxel and the ceramide is C6-ceramide. In other embodiments the antitumor

chemotherapeutic agent is a compounds structurally related to the paclitaxel family of compounds, e.g. alkaloids. The antitumor chemotherapeutic agent in any of the above-described methods may also include but not be limited to chemotherapeutic agents such as doxorubicin, cis-platin, cyclophosphamide, etoposide, vinorelbine, vinblastin, tamoxifen, colchinin, 2-methoxyestradiol. In further embodiments of the above- described methods the paclitaxel may be used together with another antitumor chemotherapeutic; combinations of any of the above-listed antitumor chemotherapeutic agents may be used. In still further embodiments of the above-described methods the ceramide may be a C2-ceramide, C8-ceramide or a higher order of ceramide. In additional embodiments more than one ceramide may be administered to the subject.

This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter.

EXPERIMENTAL DETAILS

METHODS AND MATERIALS

5 1st Series of Experiments

Paclitaxel-induced Apoptosis in Jurkat, a Leukemic T Cell Line, Is Enhanced by Ceramide

10 It is hypothesized that the lipid second messenger, ceramide, and microtubule-directed chemotherapeutic agents might engage converging pathways in inducing apoptosis. The studies described herein demonstrate that simultaneous treatment of Jurkat cells with paclitaxel and ceramide enhanced paclitaxel-induced cell growth inhibition. Cell-cycle analysis indicated a significant increase in the hypodiploid population over that observed with paclitaxel treatment alone. Morphologic evaluation and a TUNEL assay confirmed a dramatic increase in apoptosis in Jurkat cells treated with the combination of these two agents. This is the first demonstration that paclitaxel and ceramide interact in a supra-additive manner to decrease leukemic T-cell growth, suggesting a possible application of paclitaxel and ceramide in combination therapy.

MATERIALS AND METHODS

30 Cell Proliferation Assays. Jurkat, a human acute T cell leukemia line (American Type Culture Collection, Rockville, MD) was routinely maintained in an incubator at 37°C and 5% CO₂ at a density of 0.5×10^6 cells/ml in complete RPMI 1640 medium containing 1% L-glutamine, 1% penicillin-streptomycin (GIBCO Biological Research Laboratories, Grand Island, NY) and 10% - 20% fetal bovine serum (Atlanta Biologicals, Atlanta, GA). For proliferation assays, cells were washed twice and resuspended in complete RPMI 1640 medium at a density of 0.5×10^6 cells/ml in a final volume of 0.2 ml per well in

a 96-well microtiter plate. Paclitaxel (Bristol-Myers Squibb Co., Princeton, NJ) and ceramide were added as indicated below. DNA synthesis was assessed by the addition of ^3H -thymidine ($1\ \mu\text{Ci}/\text{well}$; specific activity - $6.7\ \text{Ci}/\text{mmol}$; ICN Pharmaceuticals, Costa Mesa, CA) uptake 24 hours before the end of the 72 hour growth period at a final concentration of $1\ \mu\text{Ci}/\text{well}$. Cells were harvested on glass microfibre filters (Whatman Co., Maidstone, England) with a cell harvester (Cambridge Technology, Cambridge, MA) and counted on a LKB Wallac 1214 RackBeta 'Excel' Beta spectrophotometer (Wallac Oy, Turku, Finland) after the addition of an 0.5-ml EcoLite (ICN Pharmaceuticals, Costa Mesa, CA) scintillation cocktail.

Paclitaxel and ceramide treatment of cell cultures.

Paclitaxel was added to Jurkat cell cultures at final concentrations ranging from 0.006 to 6000 ng/ml. Exogenous ceramide (C_6 -N-hexanoyl-D-sphingosine; Sigma Chemicals, St. Louis, Mo) was dissolved in 100% ethanol, and, after dilution with culture medium, was added to cell cultures at final concentrations ranging from 5 to 25 $\mu\text{g}/\text{ml}$. An equal proportion of 100% ethanol was diluted in complete RPMI 1640 medium and added to cell cultures in the absence of ceramide to eliminate the possibility of alcohol cytotoxicity. To examine the effects of combination treatment, paclitaxel (0.6 ng/ml and 6.0 ng/ml) and ceramide (25 $\mu\text{g}/\text{ml}$) were added simultaneously at the beginning of cell culture.

Cell Cycle Analysis. Cells were cultured in 6-well plates (Falcon Products, St. Louis, Mo) at a density of 0.5×10^6 cells/ml and incubated in parallel experiments with paclitaxel alone at 0.6 ng/ml and 6.0 ng/ml, ceramide alone at 25 $\mu\text{g}/\text{ml}$, and paclitaxel and ceramide in combination at 0.6 ng/ml and 6.0 ng/ml and 25 $\mu\text{g}/\text{ml}$ respectively. A 3 ml aliquot was obtained from each 6-well plate at the indicated times. Cells were

centrifuged twice at 1500 rpm for 5 minutes and resuspended in saline, labeled with 0.5 ml of propidium iodide (0.05 mg/ml), and analyzed by FACScan (Becton Dickinson Immunocytometry Systems, San Jose, CA) using ModFit LT software for cell-cycle analysis essentially as described by Look et al.(34) Cell growth was calculated as a percentage of the total population of both live and hypodiploid cells. Pie graphs (Figures 3A-F) were generated and normalized to a control value of 100%.

Histologic Evaluation. Cytospins (Shandon Incorporated, Pittsburgh, PA) of Jurkat cells treated with 0.6 ng/ml and 6.0 ng/ml paclitaxel and/or 25 µg/ml of ceramide were generated by centrifuging the cells onto glass slides (200-µl aliquot/slide) for 3 minutes at 750 rpm. Wright's stains of all slides were performed using an automated Hemastainer (Geometric Data, Wayne, PA). Slides were analyzed microscopically, photographed (Olympus BH 2, Tokyo, Japan) at 100, 200, and 400 power, and evaluated for morphological changes.

Terminal deoxynucleotide transferase (TdT) mediated deoxyuridine triphosphate (dUTP) nick-end labeling (TUNEL) assay. Jurkat cells were cultured in 6-well plates at a density of 0.5×10^6 /ml in a total volume of 5 ml, in RPMI complete medium containing 10% fetal bovine serum at 37°C; the cells were treated with and without 0.6 ng/ml of paclitaxel, 12.5 and 25 µg/ml of ceramide, or a combination of the two. At 24 and 48 hours, DNA strand breaks were labeled with TUNEL assay (In Situ Cell Death Detection Kit, Fluorescein; Boehringer Mannheim, Indianapolis, IN), and cellular apoptosis was measured by flow cytometry.

RESULTS

Initial experiments focused on the effects of varying

concentrations of ceramide on paclitaxel-mediated inhibition of Jurkat cell growth, as measured by ³H-thymidine uptake assay. Jurkat cells were plated in the presence of different amounts (0 to 50 µg/ml) of C₆-ceramide and/or paclitaxel (0 to 60 ng/ml) in RPMI-1640 culture medium containing 10% fetal bovine serum. As indicated in Fig. 1, paclitaxel at concentrations higher than 0.06 ng/ml effectively blocked thymidine incorporation of Jurkat cells. The calculated ED₅₀ for paclitaxel alone (n=5) was approximately 0.5 ng/ml in a 3-day exposure assay. Ceramide addition produced a marked enhancement of paclitaxel-mediated growth inhibition at 0.6 ng/ml, increasing from 56.5% to 90.1% and >99% (with 25 and 50 µg/ml of ceramide, respectively). Ceramide added alone did not cause significant Jurkat cell growth inhibition (≤6%) at all test concentrations (Fig. 1, Table 1).

TABLE 1Taxol and ceramide-induced growth inhibition^a

Additions	Experiment 1	Experiment 2	Experiment 3	Experiment 4	Experiment 5
None	382839±23416	444400±17569	258826±39243	301150±25159	242529±38947
Ceramide 25µg/ml	378245±28689	415740±6168	301993±67599	259230±54914	189052±3534
Taxol 0.6 ng/ml	52675±7478	95563±6427	22771±5113	89621±17579	98694±32045
Taxol 0.6 ng/ml and Ceramide 25µg/ml	24149±2688	48356±2777	1652±21	70929±16035	449±143
Taxol 6.0 ng/ml	16592±782	33443±17976	13400±849	35466±7576	10295±353
Taxol 6.0 ng/ml and Ceramide 25µg/ml	11509±965	8536±608	1262±288	8907±2484	249±147

^aThis table demonstrates that ceramide consistently enhances taxol mediated cell growth inhibition over a series of several experiments. The numbers displayed are actual [³H]thymidine uptake counts±SD (cpm), obtained from triplicate determination. A paired student *t* test demonstrated statistical significance within a 95% confidence interval.

Since earlier studies indicated that variation of serum concentration affects ceramide-mediated growth inhibition, (26,35) Jurkat cell growth inhibition in cells cultured in the presence of ceramide and/or paclitaxel with varying amounts of serum was investigated (**Fig. 2**). Ceramide-mediated growth inhibition was more pronounced (>99%) at low serum (1%) levels compared with that observed in high serum ($\geq 5\%$) conditions. Growth inhibition in cultures treated with paclitaxel alone was unaffected by variation of serum levels from 10% to 1%. Combination of paclitaxel (0.6 ng/ml) and ceramide in 10% serum inhibited growth $\geq 61\%$ more than paclitaxel alone (n=5) (**Fig. 2**).

In the next series of experiments it was sought to establish the effect of ceramide on paclitaxel-induced arrest of cell cycle growth measured at 24 hours (**Figures 3A- 3F**). Analysis of untreated Jurkat cells at the beginning of culture revealed that 51.7% of the cell population was in G_0 - G_1 phase, 32.9% in S phase, and 9.4% in G_2 -M phase (data not shown). After 24 hours, the percentage of cells in G_0 - G_1 decreased by 18.4% with a concurrent equivalent S-phase augmentation, which suggested significant cell growth after the addition of fresh culture medium (**Fig. 3A**). The cell cycle pattern following ceramide treatment in the presence of 10% fetal bovine serum did not differ from the non-ceramide-exposed control at 24 hours (**Fig. 3B**).

The addition of 0.6 or 6.0 ng/ml paclitaxel alone at 24 hours resulted in the accumulation of 22.2% and 38.2%, respectively, of the total cell population in the G_2 -M phase compared with 12.6% of the untreated cell control. This 2-3 fold increase in the G_2 -M cell population was followed by 13.3% or 23.5% decrease of cells in the G_0 - G_1 phase, thus confirming the known action of paclitaxel (**Figs. 3C and 3E**). In Jurkat cells treated with a combination of either 0.6 or 6.0 ng/ml paclitaxel and

ceramide, cell populations decreased to approximately 10% in G₂-M phase and 8.8% and 0.9% in S phase (in contrast to 31.8% and 27% with paclitaxel alone). Therefore combined treatment seems to eliminate cells from the S- and G₂-M phases (Figs. 3D and 3F).

Flow-cytometric analysis also indicated the presence of hypodiploid (sub-G₁) cell population (Figs. 3A-3F). Compared with untreated control values of 10%, treatment with 0.6 and 6.0 ng/ml paclitaxel each resulted in hypodiploid populations of approximately 25%. The addition of ceramide to paclitaxel-treated cultures demonstrated a substantial accumulation (to 60%-79%) of hypodiploid cells. These findings indicate that low thymidine uptake in combined paclitaxel and ceramide-treated cultures is not only the consequence of cell growth arrest but also possibly of cell death.

To observe the morphological changes induced by paclitaxel, ceramide, and their combination, a Wright's stain analysis of sample cultures was performed after 48 hours' treatment (Fig. 4). Fig. 4A illustrates the morphological features of normal Jurkat cells at 48 hours. A high nuclear-to-cytoplasmic ratio was evident, and all cell membranes were intact with abundant cytoplasmic granules present. Ceramide-treated cell populations were morphologically indistinguishable from control cells in 10% serum (Fig. 4B). In contrast, apoptotic bodies were noted amid cell shrinkage and nuclear and membrane blebbing following treatment with 0.6 and 6.0 ng/ml of paclitaxel alone (Figs. 4C and 4D). When ceramide and 0.6 and 6.0 ng/ml of paclitaxel were added in combination, more extensive features of cell death, including a loss of cell membrane and cytoplasmic contents, were apparent (Figs. 4E and 4F).

The presence of apoptosis in Jurkat cells treated with 0.6 ng/ml of paclitaxel, 12.5 or 25 µg/ml of ceramide,

and combinations of both agents was confirmed by TUNEL assay at 24 and 48 hours. Apoptosis in Jurkat cells treated with either 0.6 ng/ml of paclitaxel or 12.5 and 25 μ g/ml of ceramide alone was almost undetectable ($\leq 3\%$) at 24 hours. At 48 hours, exposure of Jurkat cells to 0.6 ng/ml of paclitaxel resulted in 19.6% apoptosis, but no significant apoptosis (0.41% and 0.33%) was observed in samples treated with 12.5 and 25 μ g/ml of ceramide, respectively, at 48 hours. The combination of 0.6 ng/ml of paclitaxel and 25 μ g/ml of ceramide resulted in 25.5% and 66.1% TUNEL-positive cells at 24 and 48 hours, respectively, demonstrating supra-additive enhancement of cell death (Figs. 5A-5H).

DISCUSSION

Although synergy between paclitaxel and many other chemotherapeutic agents, such as vincristine and etoposide,³¹⁻³³ has proven effective in cancer cell growth inhibition, this study is the first to characterize ceramide enhancement of paclitaxel-mediated growth inhibition. Paclitaxel-induced cell growth inhibition of Jurkat leukemic cells occurred optimally at an ED₅₀ of approximately 0.5 ng/ml, in agreement with widely cited findings that identify paclitaxel as a growth-inhibitory agent for many human leukemic cell lines.³⁶⁻³⁹ Furthermore, it was observed that the level of growth inhibition by ceramide depends on serum concentration. The observation of the absence of ceramide-induced cell growth inhibition in 10% serum in Jurkat T cells paralleled studies that showed a reduction in ceramide-induced cell growth inhibition in cell lines CMK-7, HL-60, and U937.³⁵ Interestingly, the enhancement of paclitaxel action by ceramide was not affected by high serum concentrations.

Paclitaxel and ceramide have been reported to arrest the growth of cells in the G₂-M and G₀-G₁ phases of the cell cycle, respectively. (12, 13, 25-27) In the cell cycle

studies described herein, the percentage of cells in G_0 - G_1 was almost identical in both ceramide-treated and untreated cell cultures, consistent with the lack of effect on 3H -thymidine uptake under these conditions. A significant change was found in the percentage of cells in S phase after paclitaxel treatment, indicating the loss of active DNA synthesis by Jurkat cells. The hypodiploid population of cells treated with the combination of paclitaxel and ceramide increased significantly compared to those treated with paclitaxel or ceramide alone. Paclitaxel addition at 0.6 and 6.0 ng/ml yielded G_2 -M/ G_0 - G_1 ratios of 1.11 and 3.9, respectively, consistent with the known action of paclitaxel as a G_2 -M blocker of the cell cycle.(12,13) Combinations of paclitaxel (0.6 and 6.0 ng/ml) and ceramide (25 μ g/ml) demonstrated G_2 -M/ G_0 - G_1 ratios of 0.54 and 1.0, respectively, indicating that the cell population being eliminated was also from the G_2 -M phase, in addition to S phase, resulting in cell death. These results were consistent with TUNEL assay and also by histological evaluation utilizing the Giemsa-Wright(40) staining technique.

Previous studies have demonstrated activation of Fas expression on leukemic cells by another mitotic spindle agent, vincristine, which differs from paclitaxel in that it acts by degrading the mitotic spindle in G_2 -M phase.(28-30) Ceramide enhancement of paclitaxel-mediated apoptosis may possibly be attributed to a mechanism similar to that of the activation of Fas on the surface of Jurkat cells.(15,22,41-42) It is hypothesized that paclitaxel enhances intracellular ceramide production by increasing acid sphingomyelinase activity by the engagement of either Fas receptor or another homologous TNF receptor such as DR4.(43) This enhancement of intracellular ceramide levels is further augmented by the addition of exogenous ceramide. Recent studies have

shown that paclitaxel is capable of upregulating Fas
ligand expression.(29,44) It may be possible that
paclitaxel/ceramide mediated enhancement is due to
upregulation and release of Fas ligand from the surface
of Jurkat cells and into the surrounding cell culture
media, which can then induce cellular suicide by ligating
Fas on the cell membrane. Such a mechanism has been
proposed in activation-induced death of Jurkat cells
whereby APO2/TRAIL ligand, a TNF homologue, binds to
newly discovered DR4 receptor.(43)

While the role of Fas mediated events during paclitaxel
exposure is unknown, recent reports have disputed the
role of the generation of ceramide in apoptosis by
suggesting that ceramide is either not involved in
Fas-mediated apoptosis or is not a critical component of
the initial apoptotic events and may instead act
downstream of the cascade.(45-47) However, none of
these studies measured intracellular ceramide levels at
high serum concentrations, which, the present study
shows, may profoundly affect the role in leukemic cell
apoptosis. The present study suggests that cell apoptosis
mediated by paclitaxel and ceramide may be linked by a
common signal transducing pathway leading to cell death.

References for First Series of Experiments

- 5 1. Slichenmyer, W.J., Von Hoff D.D., Taxol: a new and effective anti-cancer drug. *Anticancer Drugs* , 1991, 2, 519.
- 10 2. Zoli, W., Flamigni, A., Frassinetti, G.L., Bajorko, P., De Paola, F., Milandri, C., Amadori, D., Gasperi-Campani, A.: *In vitro* activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers. *Breast Cancer Res. Treat.*, 1995, 34, 63.
- 15 3. McGuire, W.P., Rowinsky, E.K., Rosenshein, N.B., Grumbine, F.C., Ettinger, D.S., Armstrong, D.K., Donehower, R.C., Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. *Ann. Int. Med.*, 1989, 111, 273.
- 20 4. Silvestrini, R., Zaffaroni, N., Orlandi, L., Oriana, S.: *In vitro* cytotoxic activity of Taxol and Taxotere on primary cultures and established cell lines of human ovarian cancer. *Stem Cells (Dayt)* , 1993, 11, 528.
- 25 5. Yamori, T., Sato, S., Chikazawa, H., Kadota, T.: Anti-tumor efficacy of paclitaxel against human lung cancer xenografts. *Jpn. J. Cancer Res.*, 1997, 88, 1205.
- 30 6. Akutsu, M., Kano, Y., Tsunoda, S., Suzuki, K., Yazawa, Y., Miura, Y.: Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell lines *in vitro*. *Eur. J. Cancer* , 1995, 31A, 2341.
- 35 7. Elomaa, L., Joensuu, H., Kulmala, J., Klemi, P., Grenman, R.: Squamous cell carcinoma is highly sensitive to taxol, a possible new radiation sensitizer. *Acta Otolaryngol. (Stockh)* , 1995, 115, 340.

8. Spencer, C.M., Faulds, D., Paclitaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. *Drugs*, 1994, **48**, 794.
9. Huizing, M.T., Misser, V.H., Pieters, R.C., ten Bokkel Huinink, W.W., Veenhof, C.H., Vermorken, J.B., Pinedo, H.M., Beijnen, J.H., Taxanes: a new class of antitumor agents. *Cancer Invest.*, 1995, **13**, 381.
10. Rowinsky, E.K., Donehower, R.C., Jones, R.J., Tucker, R.W., Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. *Cancer Res.*, 1988, **48**, 4093.
11. Kumar, N., Taxol-induced polymerization of purified tubulin. Mechanism of action. *J. Biol. Chem.*, 1981, **256**, 10435.
12. Milross, C.G., Mason, K.A., Hunter, N.R., Chung, W.K., Peters, L.J., Milas, L., Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. *J. Natl. Cancer Inst. Monograph*, 1996, **88**, 1308.
13. Milas, L., Hunter, N.R., Kurdoglu, B., Mason, K.A., Meyn, R.E., Stephens, L.C., Peters, L.J., Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. *Cancer Chemother. and Pharmacol.*, 1995, **35**, 297.
14. Gangemi, R.M., Costa, G., Fulco, R.A., d'Aquino, S., Aronadio, O., Apoptosis susceptibility of human carcinoma and leukemia cell lines to taxol. Relationship with cell cycle and drug concentration. *Ann. N. Y. Acad. Sci.*, 1996, **784**, 550.
15. Cifone, M.G., De Maria, R., Roncaioli, P., Rippo,

M.R., Azuma, M., Lanier, L.L., Santoni, A., Testi, R., Apoptotic signalling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase. *J Exp Med.*, 1994, 180, 1547.

- 5 16. Testi, R., Sphingomyelin breakdown and cell fate. *Trends in Biochem Sci*, 1996, 21, 468.
- 10 17. Jarvis, W.D., Grant, S., and Kolesnick, R.N., Ceramide and the induction of apoptosis. *Clin Cancer Res.*, 1996, 2, 1.
- 15 18. Obeid, L.M., Hannun, Y.A., Ceramide: a stress signal and mediator of growth supression and apoptosis. *J Cell Biochem.*, 1995, 58, 191.
- 20 19. Obeid, L.M., Linardic, C.M., Karolak, L.A., Hannun, Y.A., Programmed cell death induced by ceramide. *Science*, 1993, 259, 1769.
- 25 20. Ji, L., Zhang, G., Uematsu, S., Akahori, Y., Hirabayashi, Y., Induction of apoptotic DNA fragmentation and cell death by natural ceramide. *FEBS Letters*, 1995, 358, 211.
- 30 21. Hannun, Y.A., Obeid, L.M., Ceramide: an intracellular signal for apoptosis. *Trends in Biochem Sci*,, 1995, 20, 73.
- 35 22. Tepper, C.G., Jayadev, S., Liu, B., Bielawska, A., Wolff, R., Yonehara, S., Hannun, Y.A., Seldin, M.F., Role for ceramide as an endogenous mediator of Fas-induced cytotoxicity. *Proc. Natl. Acad. Sci.* , 1995, 92, 8443.
23. Kolesnick, R.N., Haimovitz-Friedman, A., Fuks, Z., The sphingomyelin signal transduction pathway mediates apoptosis for tumor necrosis factor, Fas, and ionizing radiation. *Biochem. and Cell Biol.*, 1994, 72, 471.

24. Jarvis, W.D., Kolesnick, R.N., Fornari, F.A.,
Traylor, R.S., Gewirtz, D.A., and Grant, S., Induction
of apoptotic DNA damage and cell death by activation of
the sphingomyelin pathway. *Proc. Natl. Acad. Sci.* ,
5 1994, 91, 73.
25. Kuroki, J., Hirokawa, M., Kitabayashi, A., Lee, M.,
Horiuchi, T., Kawabata, Y., Miura, A.B., Cell-permeable
ceramide inhibits growth of B lymphoma Raji cells lacking
10 TNF-alpha receptors by inducing G₀/G₁ arrest but not
apoptosis: a new model for dissecting cell-cycle arrest
and apoptosis. *Leukemia* , 1996, 10, 1950.
26. Jayadev, S., Liu, B., Bielawska, A.E., Lee, J.Y.,
15 Nazaire, F., Pushkareva, M. Yu, Obeid, L.M., Hannun,
Y.A., Role for ceramide in cell cycle arrest. *J. Biol.*
Chem. , 1995, 270, 2047.
27. Venable, M.E., Lee, J.Y., Smyth, M.J., Bielawska,
20 A., Obeid, L.M., Role of Ceramide in Cellular
Senescence. *J. Biol. Chem.* , 1995, 270, 30701.
28. Hirose, Y., Takiguchi, T., Microtubule changes in
hematologic malignant cells treated with paclitaxel and
25 comparison with vincristine cytotoxicity. *Blood Cells and*
Mol. Dis., 1995, 21,119.
29. Roth, W., Fontana, A., Trepel, M., Reed, J.C.,
Dichgans, J., Weller, M., Immunotherapy of malignant
30 glioma: synergistic activity of CD95 ligand and
chemotherapeutics. *Cancer Immunol. and Immunotherapy*,
1997, 44, 55.
30. Efferth, T., Fabry, U., Osieka, R., Anti-Fas/Apo-1
35 monoclonal antibody CH-11 depletes glutathione and kills
multidrug-resistant human leukemic cells. *Blood Cells*
and Mol. Dis. , 1996, 22, 2.
31. Curtis, J.E., Minkin, S., Minden, M.D., McCulloch,

- E.A., A role for paclitaxel in the combination chemotherapy of acute myeloblastic leukaemia: preclinical cell culture studies. *Br. J. Haematol.*, 1996, **95**, 354.
- 5 32. Brooks, D.J., Alberts, D.S., A phase I study of etoposide phosphate plus paclitaxel. *Sem. Oncol*, 1996, **23**, 33.
- 10 33. Knick, V.C., Eberwein, D.J., Miller, C.G., Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells. *J. Natl. Cancer Inst. Monograph*, 1995, **87**, 1072.
- 15 34. Look, A.T., Melvin, S.L., Williams, D.L., Brodeur, G.M., Dahl, G.V., Kalwinsky, D.K., Murphy, S.B., Mauer, A.M., Aneuploidy and percentage of S-phase cells determined by flow cytometry correlate with cell phenotype in childhood acute leukemia. *Blood*, 1982, **60**, 959.
- 20 35. Sweeney, E., Sakakura, C., Shirahama, T., Masamune, A., Ohta, H., Hakomori, S., Igarashi, Y., Sphingosine and its methylated derivative N,N dimethylsphingosine (DMS) induce apoptosis in a variety of human
- 25 cancer cell lines. *Int. J. Cancer*, 1996, **66**, 358.
- 30 36. Rowinsky, E.K., Burke, P.J., Karp, J.E., Tucker, R.W., Ettinger, D.S., Donehower, R.C.: Phase I and pharmacodynamic study of taxol in refractory acute leukemias. *Cancer Res.*, 1989, **49**, 4640.
- 35 37. Li, X., Gong, J., Feldman, E., Seiter, K., Traganos, F., Darzynkiewicz, Z., Apoptotic cell death during treatment of leukemias. *Leukemia and Lymphoma*, 1994, **13 Suppl 1**, 65.
38. Gangemi, R.M., Tiso, M., Marchetti, C., Severi, A.B., Fabbi, M., Taxol cytotoxicity on human leukemic

cell lines is a function of their susceptibility to programmed cell death. *Cancer Chemotherapy and Pharmacol.*, 1995, 36, 385.

5 39. Auber, M.L., Horwitz, L.J., Blaauw, A., Khorana, S., Tucker, S., Woods, T., Warmuth, M., Dicke, K.A., McCredie, K.B., Spitzer, G.: Evaluation of drugs for elimination of leukemic cells from the bone marrow of patients with acute leukemia. *Blood*, 1988, 71, 166.

10 40. Ray, S., Ponnathpur, V., Huang, Y., Tang, C., Mahoney ME, Ibrado AM, Bullock G, Bhalla, K., 1-beta-D-arabinofuranosylcytosine-, mitoxantrone-, and paclitaxel- induce apoptosis in HL- 60 cells: Improved method for detection of internucleosomal DNA
15 fragmentation. *Cancer Chemotherapy and Pharmacol.*, 1994, 34, 365.

20 41. Ballou, L., Laulederkind, S., Rosloniec, E; Raghov, R: Ceramide signalling and the immune response. *Biochim. et Biophys. Acta.* , 1996, 1301, 273.

25 42. Herr, I., Wilhelm, D., Böhler, T., Angel, P., Debatin, K.M., Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy- induced apoptosis. *EMBO J.*, 1997, 16, 6200.

30 43. Martinez-Lorenzo, M.J., Alava, M.A., Gamen, S., Kim, K.J., Chuntharapai, A., Piniero, A., Naval, J., Anel, A., Inovlvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells. *Eur. J. Immunol.* 1998, 28, 2714.

35 44. Roth, W., Wagenknecht, B., Grimm, C., Dichgans, J., Weller, M., Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest. *Br. J. Cancer* , 1998, 77, 404.

- 5

- 10

- 15

2nd Series of Experiments

Effects of Paclitaxel and Ceramide on Human Squamous Carcinoma Cell Line Tu138 in Vitro and in Vivo

The purpose of this study was to observe in vitro and in vivo effects (additive or synergistic) of combining paclitaxel and ceramide in inducing cytotoxicity and apoptosis in human squamous carcinoma cells (Tu138). Synergistic cytotoxic and apoptic action of these two agents in vitro in other neoplastic cell lines have been previously demonstrated.

METHODS

The effects of paclitaxel and ceramide on cell growth of Tu138 was evaluated by MTT dye assay (see infra p. 35), cell cycle progression by flow cytometry (see infra pp. 35-36), cell apoptosis by TUNEL assay (see infra pp. 35-36) and tumor growth and weight in nude mice (see infra pp. 37-38). To corroborate in vitro findings Tu138 cells were planted subcutaneously on nude mice. Treatment with paclitaxel (120 μ g/0.1mL) + ceramide (500 μ g/0.2mL) was begun on day 4 with thrice weekly injections administered subcutaneously near the tumor site for 5 weeks. Other treatment groups included: vehicle only, paclitaxel alone and ceramide alone. Tumor size was measured once a week. All groups of mice were sacrificed on day 45 and excised tumors were weighed.

RESULTS

Cell growth studies showed synergystic growth inhibition with paclitaxel + ceramide and was confirmed by a 50% isobologram analysis in six separate experiments (p value <0.05). The TUNEL assay also confirmed enhanced apoptosis by the combined treatments. Cell cycle progression studies suggested that the target population

of cells was either in the S or G₂-M phase of the cell cycle. Preliminary in vivo studies showed equivalent growth of Tul38 cell-tumor in control and paclitaxel treated mice whereas the ceramide injected group showed a slight decrease in tumor size at week 5. The paclitaxel + ceramide group showed a decline of 70% in tumor size compared to control group. There was also significant reduction in tumor weight (88% in paclitaxel + ceramide group vs. control). The ceramide only group also had a substantial reduction in tumor weight. The excised tumors are being studied to determine tumor cell morphology and cellular apoptosis.

DISCUSSION

Paclitaxel and ceramide are synergistic in inducing apoptosis and cytotoxicity in the Tul38 squamous cell line in vitro. In vivo effects on tumor growth and weight are similar suggesting preclinical therapeutic potential of these agents.

3rd Series of Experiments

COMBINED CYTOTOXIC ACTION OF PACLITAXEL (TAXOL) AND CERAMIDE ON HUMAN TU138 SQUAMOUS CARCINOMA CELL LINE OF THE HEAD AND NECK

Increased intracellular ceramide levels can be induced by a variety of agents including TNF α , Fas, ionizing radiation and chemotherapeutic agents causing apoptosis in several cell systems. Exogenous ceramide can also induce apoptosis by raising intracellular levels. Paclitaxel (taxol), a highly efficacious chemotherapeutic drug, used in the treatment of recalcitrant ovarian and breast as well as other neoplasms, is now undergoing Phase II trials in squamous cell carcinoma of the head and neck. This study shows that paclitaxel and ceramide both induce apoptosis in a human squamous carcinoma cell

line Tu138, with an ED_{50} of 1920 ± 1200 ng/ml and 22 ± 5 μ g/ml respectively. Ceramide combined with paclitaxel induced cytotoxic effects which were synergistic in greater than 75% of the experimental combinations tested, based on isobologram analysis. The synergy in cell kill was confirmed by TUNEL assay. Flow cytometric analysis of the combination treatment indicated elimination of Tu138 cells from S and/or G_2 -M phases of the cell cycle. This synergistic combination may have therapeutic application in the treatment of head and neck cancer. The mechanism of synergistic action between these two agents may involve a commonality in signal transduction pathways induced by paclitaxel and ceramide.

Sphingolipids have been shown to be biologically active and have numerous regulatory effects on cell function including cell growth and differentiation. A number of inducers of sphingomyelin hydrolysis causing concomittant elevation of intracellular ceramide have been identified. These include $TNF\alpha$, endotoxins, interferon α , IL-1, Fas ligand, CD28, chemotherapeutic agents, heat and ionizing radiation (1, 2). The kinetics of endogeneous ceramide formation and accumulation appear to be complex and variable in different cell systems and with different inducers of sphingomyelin catabolism (3-6). It has recently been established that endogenously generated ceramide acts as a second messenger and induces apoptosis (7). Ceramide synthesis *de novo* has been implicated in lethal responses to several chemotherapeutic agents such as anthracyclines (8) and ara-C (9). Many recent studies have examined the effect of exogeneous ceramide on the induction of apoptosis in a variety of tumor cells. Ceramide has been shown in such cases to cause cell cycle arrest in several cell lines as well as apoptosis, cell senescence and terminal differentiation (10-13).

Paclitaxel is a chemotherapeutic drug with ability to

block growing cells in the G₂-M phase of the cell cycle (14). This is due to the fact that paclitaxel treated cells cannot undergo the microtubule depolymerization step to cytokinesis. In addition many paclitaxel mediated effects are known including bcl-2 phosphorylation (15) and the involvement of apoptosis via BAX, a bcl-2 dimerization product (16). Paclitaxel is currently being used in a variety of different cancers in clinical trials, alone and in combination with a variety of chemotherapeutic agents. (17-18) and has been shown to induce high rates of clinical responses in patients with squamous cell cancer of the head and neck (19). Neurotoxicity and myelosuppression seem to be the major limiting factors associated with paclitaxel treatment, hence there have been numerous studies combining other drug therapies with paclitaxel to increase its therapeutic efficacy. The purpose of the present studies was to examine if paclitaxel induced apoptosis can be enhanced by the addition of exogeneously added ceramide.

Materials and Methods

Tumor Cell Line:

Tu138, an adherent squamous carcinoma cell line of the head and neck was established at U T M D Anderson Cancer Center, Houston, TX (20, 21) and was generously provided by Dr. Gary Clayman's laboratory. Tu138 cells were maintained routinely in T-75 culture flasks (Falcon, Inc., NJ) at a plating cell density of 0.1×10^6 per 75 sq. cm. surface area in complete D-MEM/F-12 culture medium (10 ml) containing 10% fetal bovine serum (FBS, Atlanta Biologicals, GA), 2 mM glutamine (Gibco, NY), 50 units/mL penicillin, 50 mg streptomycin (Gibco, NY) and 20 mM Hepes (Sigma, MO) in a 5% CO₂ atmosphere at 37°C. Tu138 cells were replenished with fresh complete culture medium twice weekly until confluence.

Treatment of Tu138 Tumor Cell Line with Drugs

For exposures to paclitaxel (taxol) and/or ceramide Tu138 cells were trypsinized in 0.25% trypsin-EDTA solution, washed twice in DMEM and plated in 96-well culture plates at a concentration of 2×10^4 in a final volume of 0.2 ml in D-MEM/F-12 with 10% FBS and incubated in the presence or absence of different concentrations of paclitaxel (Taxol) (0-6000ng/ml; Bristol Myers Squibb, Inc., NJ) and/or ceramide (N-hexanoyl-D-sphingosine, 0-25 μ g/ml; Sigma Chemicals, MO). At the indicated times (24 to 72 hours), cells were subjected to (a) tetrazolium-based dye assay for cell survival measurements, (b) flow cytometry analysis for cell cycle progression and (c) measurements of apoptosis by TUNEL assay.

MTT Assay

For the measurement of cellular cytotoxicity, 50 μ l of 0.2% solution of MTT [3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide] dye (Sigma Chemicals, MO) was added to Tu138 cells after treatment with paclitaxel and/or ceramide and incubated at 37°C (22). At the end of an incubation period of 4 hours, culture plates were centrifuged at 300g for 2 minutes. After removal of the culture medium, 150 μ l of DMSO was added to solubilize MTT formazan crystals formed by cells undergoing coupled respiration and optical density was determined by the use of ELISA reader (Model EL 311, Biotek Inc.) at 540 nm.

Cell Cycle Measurements and TUNEL Assay

In concurrence with the MTT dye assay, Tu138 cells were plated in 6-well culture dishes at a concentration of 2×10^6 in a volume of 4 ml in D-MEM/F-12 containing 10% FBS at 37°C and exposed to paclitaxel (600 ng/ml) and/or ceramide (25 μ g/ml). At the end of either 24 or 48

hours, cells were trypsinized and washed with the culture medium. For cell cycle measurements, cells were mixed with 0.5 ml of 0.1% propidium iodide solution (New Concepts Scientific Ltd. ON) containing 0.1% sodium citrate and 0.1% NP-40. RNase (1 μ g) was added to each sample and cells were incubated at 4°C for 30 minutes. At least 1×10^4 cells were acquired on a precalibrated FACScan (Beckton Dickinson, CA) flow cytometer. For precalibration "DNA QC" (Becton Dickinson, CA) kit was utilized. The acquired cells were then subjected to cell cycle analysis by the use of "Modfit LT" software (Beckton Dickinson, CA). For measurements of apoptosis, In Situ Cell Death Detection Kit (Boehringer Mannheim, IN) followed by flow cytometry analysis was utilized.

Results

Paclitaxel and Ceramide Induced Cytotoxicity as a Function of Time of Exposure

The first set of experiments was directed to observe the cytotoxic effects of paclitaxel and ceramide at different concentrations separately on Tu138 cell line, as measured by MTT dye assay. As shown in **Figure 6A**, paclitaxel (Taxol) induced cytotoxicity was observed to be 37% and 64% at 600 and 6000 ng/ml respectively whereas ceramide induced cell effects after 3 days of culture resulted in 19% and 46% cytotoxicity at 12.5 and 25 μ g/ml concentrations respectively (**Figure-6B**). Multiple repeats (n=6) of these experiments indicated paclitaxel and ceramide induced ED₅₀ at concentrations of 1920 ± 1200 ng/ml and 22 ± 5 μ g/ml respectively.

To evaluate whether the paclitaxel and ceramide combination enhances cellular cytotoxicity caused by either alone, Tu138 cells were incubated with and without paclitaxel (600 ng/ml) and ceramide (25 μ g/ml) simultaneously and separately as control. Cell viability was estimated using the MTT dye assay as a function of

time every 24 hours over a period of 3 days. As shown in Figure 7, paclitaxel (Taxol) when added alone at a concentration of 600 ng/ml indicated cell cytotoxicity from 0.9% at 24 hours to a total of 21.8% by 72 hours. Ceramide also showed an increase in cytotoxicity from 32.7% at 24 hours to 54.5% at 72 hours. The combination of paclitaxel (600 ng/ml) and ceramide (25 µg/ml) treatment showed an increase of approximately 68% in cell cytotoxicity over ceramide alone in a 3 day incubation period. The enhancement of cellular cytotoxicity was also evident in combination treatment at 24 (62.0% cell kill) hours with a maximum cell kill observed at 72 hours. From these results, the combination of both agents seems to indicate an enhancement over an additive effect with respect to a loss of electron transport and subsequent cell viability.

The results of 23 different observations of paclitaxel (600 ng/ml), ceramide (25 µg/ml) and paclitaxel (600 ng/ml) plus ceramide (25 µg/ml) combinations were then subjected to statistical analysis. The mean observed optical density (obtained after different exposures) and the standard deviation were analyzed over the confidence interval with 95% probability. The value of confidence range was compared by assuming a "Student t" distribution in the selected exposure conditions. The paired t-test for (n-1) degrees of freedom demonstrated that the results of paclitaxel and ceramide combination were significantly different with >95% probability than either paclitaxel or ceramide alone.

Synergistic Interaction Analysis by Isobologram

To confirm whether paclitaxel and ceramide interactions on Tu138 cell cytotoxicity was synergistic or additive a quantitative isobologram analysis (23, 24) of six independent experiments in triplicates was performed at various dilutions of paclitaxel (0-6000 ng/ml) and

ceramide (0-25 $\mu\text{g/ml}$) separately and simultaneously. A straight line joining points on x- and y- axes (**Figure 8**) represents ED_{50} concentrations of paclitaxel (Taxol) and ceramide as determined from six independent experiments. Because of the non-linearity of the dose response curves with either paclitaxel or ceramide alone, a second line plot was generated by calculating ED_{10} through ED_{90} for either agent alone. The line plot represents ED_{40} for paclitaxel combined with ED_{10} of ceramide or paclitaxel ED_{30} plus Ceramide ED_{20} and so on. **Figure 8** represents the isobologram using both the straight line approximation and curve generated from the experimental data to compare the effect of combined additions on synergy. The points to the left of the two line plots that fall within ED_{50} concentrations indicate supra-additive properties of two agents tested in combination. The isobologram analysis indicated that six experiments represented as scatter plots are supra additive. The linear approximation consideration indicated 21 out of 23 experimental points to be synergistic. The experimental determination showed 18 of 23 points in the synergistic range.

Paclitaxel and Ceramide Effects on Cell Cycle Distributions

Paclitaxel and ceramide effects have been implicated in cell cycle arrest and apoptosis. To examine whether the interactions of paclitaxel with ceramide would affect the kinetics of cell cycle progression, paclitaxel at 600 ng/ml and ceramide at 25 $\mu\text{g/ml}$ concentrations (at or near ED_{50} 's) were utilized to measure the distribution of cells during growth by flow cytometer utilizing propidium iodide staining technique. Since it was difficult to obtain enough viable cells in a sample where combination treatment was utilized after 72 hour exposures, cell cycle measurements were made only at 24 and 48 hours. As **Figure 9A-9H** demonstrate paclitaxel (Taxol) was able to

block 61.8% (24 hours) **Figure 9C** and 58.2% **Figure 9G** (48 hours) of Tu138 cells in the G₂-M phase of the cell cycle in comparison to untreated control cells (7.4% at 24 hours and 6.0% at 48 hours). Ceramide added alone did not significantly affect either G₀-G₁ or G₂-M phase of the cell cycle progression similar to untreated controls (n=4) at either 24 or 48 hours.

In cultures treated simultaneously with paclitaxel (Taxol) and ceramide, a G₂-M arrest of 45.6% (**Figure 9D**) and 28.4% (**Figure 9H**) was observed at both 24 and 48 hours respectively in comparison to paclitaxel (Taxol) treated cultures. This indicated a loss of 26.3% and 51.3% G₂-M population of viable Tu138 cells due to the combined effect of paclitaxel and ceramide in comparison to paclitaxel alone at 24 and 48 hours respectively. A significant loss of S-phase population was also observed only at 48 hours. Taken in concurrence with the MTT results, these data indicate cell death occurring either in the G₂-M phase or during the exit from the S-phase of the cell cycle.

Induction of Apoptosis by Paclitaxel Paclitaxel and Ceramide Combination

Since the MTT dye assay and the measurement of G₂-M cell population cannot determine whether loss of cells is due either to necrosis or apoptosis, and since paclitaxel and ceramide when added alone have been shown to induce apoptosis by several researchers (25, 26), the next series of experiments were directed to examine the mode of cell kill induced by combined exposures of paclitaxel and ceramide at 24 and 48 hours by TUNEL assay. As demonstrated in Figure 10A-10H, exposures of paclitaxel (Taxol) (600 ng/ml) and ceramide (25 µg/ml) alone resulted in 18.4% and 9.7% apoptosis at 24 hours respectively whereas both added together induced 53.7% apoptosis indicating an approximately 3-fold increase in

comparison to paclitaxel alone. At 48 hours, paclitaxel and ceramide individually induced a 54.8% and 13.6% apoptosis respectively when compared to observed apoptosis of 7.9% in untreated control. When the two agents were added together the percent apoptosis increased to 84.9%. In two separate experiments, paclitaxel and ceramide combinations showed 1.5-fold or greater apoptosis in comparison to paclitaxel alone at 24 and 48 hours.

Discussion

Paclitaxel has clearly been defined as an extremely important new agent in cancer chemotherapy. It has already demonstrated considerable antitumor activities against high staged and relatively resistant tumors of head and neck (18, 27-30). The present studies confirm that paclitaxel is able to arrest the head and neck carcinoma cell line Tu138 in the G₂-M phase of the cell cycle. It is also demonstrated that paclitaxel alone is cytotoxic to head and neck carcinoma cells in vitro as demonstrated by the MTT assay (ED₅₀: 1920±1200 ng/ml). The large variation in ED₅₀ value may be attributed to asynchronous population of Tu138 cells during its growth. Such cell cycle sensitivity and cytotoxicity to paclitaxel has been demonstrated in ovarian, breast, lung and numerous other cell lines (31-34).

Exogeneous addition of ceramide has been shown to cause apoptosis in a variety of tumor cell lines (10, 35). In the current studies on solid tumors of head and neck cancer origin, ceramide mediated direct cytotoxicity of Tu138 cell is observed with an ED₅₀ of 22±5 µg/ml. In addition, ceramide was shown to induce apoptosis in Tu138 cells as measured by TUNEL assay. However, no significant effect of ceramide on the cell cycle progression of Tu138 cells was demonstrated. This is in contradiction to observed G₀-G₁ cell block by ceramide in MOLT-4, a

leukemic cell line (10).

5 The combined effect of paclitaxel and ceramide, two drugs
with diverse activities, on neoplastic cell cycle
progression was examined. It is postulated that if a
chemotherapeutic drug such as paclitaxel were to enhance
the accumulation of intracellular ceramide which has been
10 suggested to be a mechanism of apoptotic cell death, then
the addition of exogeneous ceramide may increase the
threshold concentration leading to cellular cytolysis.
While data on the necessary and sufficient concentration
of intracellular ceramide to induce cytolysis is not
available from these results, it is clear that these two
agents work synergistically to induce apoptosis. This is
15 confirmed by isobologram analysis demonstrating synergy
in >78% of the tested experimental concentrations of
paclitaxel and ceramide combined.

20 These present studies demonstrate that paclitaxel (600
ng/ml) and ceramide, when added separately, are able to
kill Tu138 cells via apoptotic mechanisms within 24 hours
of exposure. However, when the two agents were combined
the observed cytotoxicity was greater than the addition
of observed cytotoxicity by paclitaxel and ceramide
25 separately indicating a synergistic interaction between
these two agents. In addition, a significant reduction
in the cell population in the G₂-M phase of the cell cycle
within 48 hours due to combined addition of paclitaxel
and ceramide was evident from the measurements of cell
30 cycle analysis. Taken together, the MTT dye and TUNEL
assay results, seem to suggest that the loss of cell
population is from either S or G₂-M phase of the cell
cycle.

35 The activation of a number of receptors including TNF α ,
interferon γ , and Fas signal an intracellular pathway
that includes sphingomyelinases which act on membrane
sphingomyelin and cause release of the lipid mediator

ceramide (36-38). Ceramide may then cause the activation of down stream signal transduction pathways that in turn seem to initiate the final phase of apoptosis involving membrane blebbing, the breakdown of DNA and proteins, fragmentation of organelles, and packaging of cellular debris into apoptotic bodies (12, 39-40). Many chemotherapeutic agents such as doxorubicin have been shown to mediate apoptosis through the involvement of Fas receptor/ligand system (41), which has been questioned in a number of recent studies (42, 43). The engagement of FasR with paclitaxel is yet to be determined. Activation of apoptosis has also been shown to occur directly, through the activation of ceramide synthase with certain chemotherapeutic drugs such as daunorubicin (8). It has been shown that paclitaxel (Taxol) mediates its apoptotic effects via phosphorylation of bcl-2 (15) or the upregulation of BAX (16). Therefore, it is postulated that the mechanism whereby paclitaxel and ceramide mediate a synergistic effect may be via a commonality in downstream signal transduction pathways.

Paclitaxel has been evaluated in combination with cisplatin, doxorubicin and radiotherapy (44-46) in patients with encouraging results. It is important that new combinations be established with better efficacies and be evaluated for patient toxicities. The present results suggest that the addition of ceramide enhances the therapeutic potential of paclitaxel for treatment of head and neck carcinoma.

References for 3rd Series of Experiments

- 5 1. Hannun, Y.A. The sphingomyelin cycle and the second messenger function of ceramide. J. Biol. Chem., 269, 3125, 1994.
2. Kolesnick, R. and Golde, D.W. The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell, 77, 325, 1994.
- 10 3. Ballou, L.R., Chao, C.P., Holness, M.A., Barker, S.C., and Raghov, R. Interleukin-1-mediated PGE2 production and sphingomyelin metabolism. Evidence for the regulation of cyclooxygenase gene expression by sphingosine and ceramide. J. Biol. Chem., 267, 20044, 1992.
- 15 4. Yanaga, F. and Watson, S.P. Ceramide does not mediate the effect of tumour necrosis factor alpha on superoxide generation in human neutrophils. Biochem. J., 298, 733, 1994.
- 20 5. Okazaki, T., Bielawska, A., Bell, R.M., and Hannun, Y.A. Role of ceramide as a lipid mediator of 1 alpha, 25-dihydroxyvitamin D3-induced HL-60 cell differentiation. J. Biol. Chem., 265, 15823, 1990.
- 25 6. Dobrowsky, R.T., Jenkins, G.M., and Hannun, Y.A. Neurotrophins induce sphingomyelin hydrolysis. Modulation by co-expression of p75NTR with Trk receptors. J. Biol. Chem., 270, 22135, 1995.
- 30 7. Venable, M.E., Lee, J.Y., Smyth, M.J., Bielawska, A, Obeid, L.M. Role of ceramide in cellular senescence. J. Biol. Chem., 270, 30701, 1995.
- 35 8. Bose, R., Verheji, M., Haimovitz-Friedman, A., Scotto, K., Fuks, Z. and Kolesnick, R. Ceramide synthase mediates daunorubicin-induced apoptosis: and alternative mechanism for generating death signals. Cell, 82:

405-414, 1995.

- 5 9. Strum, J.C., Small, G.W., Daiug, S.B. and Daniel, L.W.,
1-b-D arabinofuranosylcytosine stimulates ceramide
and diglyceride formation in HL-60 cells. J. Biol. Chem.,
269, 15493, 1994.
- 10 10. Jayadev, S., Liu, B., Bielawska, A. E., Lee, J. Y.,
Nazaire, F., Pushkareva, M., Obeid, L. M. and Hannun, Y.
A. Role for ceramide in cell cycle arrest. J. Biol.
Chem., 270, 2047, 1995.
- 15 11. Beilawska, A., Linardic, C.M., and Hannun, Y.A.
Modulation of cell growth and differentiation by
ceramide. FEBS Lett, 307, 211, 1992.
- 20 12. Obeid, L.M., Hannun, Y.A. Ceramide: a stress signal
and mediator of growth supression and apoptosis. J.
Cell Biochem., 58, 191, 1995.
- 25 13. Jarvis, W.D., Kolesnick, R. N., Fornari, F. A.,
Traylor, R. S., Gewirtz, D. A., and Grant, S. Induction
of apoptotic DNA damage and cell death by activation of
the sphingomyelin pathway. Proc. Natl. Acad. Sci USA,
91, 73, 1994.
- 30 14. Schiff, P.B., Horwitz, S.B. Taxol stabilizes
microtubules in mouse fibroblast cells. Proc. Natl. Acad.
Sci. USA , 77, 1561, 1980
- 35 15. Haldar, S., Chintapalli, J., and Croce, C.M. Taxol
induces bcl-2 phosphorylation and death of prostate
cancer cells. Cancer, 56, 1253, 1996.
16. Strobel, T., Swanson, L., Korsmeyer, S., and
Cannistra, S.A. BAX enhances paclitaxel induced
apoptosis through a p53 independent pathway. Proc. Natl.
Acad. Sci. USA, 3, 4096, 1996.

17. Holmes, F.A., Walters, R.S., Theinault, R.L., et al. Phase II trial of Taxol an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst., 83, 1797, 1991.
18. Forastiere, A.A., and Urba S.C. Simple agents paclitaxel and paclitaxel tifosfamide in the treatment of head and neck cancer. Sem Oncol., 22: 24-27, 1995.
19. Cortes-Funes, H. and Aisner, J. Paclitaxel in head and neck cancer and other tumor types. Sem. Oncol., 24, 52, 1997.
20. Liu T.J., Zhang W.W., Taylor D., Roth J., Goepfert H. and Clayman G. Growth suppression of head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res., 54, 3662, 1994.
21. Clayman, G., Liu, T, Overholt, M, Mobley, S., Wang, M., Janot, F and Goepfert, H. Gene therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg, 122, 489, 1996.
22. Carmichael, J., DeGraf, W. J., Gazdar, A. F., Minna, J. D. and Mitchell, J. B. Evaluation of a Tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res., 47, 936, 1987.
23. Elion, G B, Singer, S and Hichings G H. Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. J. Biol. Chem., 208, 477, 1954.
24. Chou, T. C. and Talalay P. Quantitative analysis of dose-effect relationships: the combined effect of

multiple drugs and enzyme inhibitors. In: Advances in enzyme regulation. G. Weber, ed, Pergamon Press, NY, pp 27-55, 1984.

- 5 25. Milross, C. G., Mason, K. A., Hunter, N. R., Chung, W, Peters, L. and Milas, L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J. Natl. Cancer Inst., 88, 1308, 1996.
- 10 26. Hannun, Y. Functions of ceramide in coordinating cellular responses to stress. Science, 274, 1855, 1996.
- 15 27. Forastiere, A.A. Paclitaxel (Taxol) for the treatment of head and neck cancer. Sem in Oncol, 21: 45, 1994.
- 20 28. Wanebo, H.J., Chougule, P., Ackerley, W., Konness, R. J., McRae, R., Nigri, P., Leone, L, Safran, H., Webber, B., Cole, B. Preoperative paclitaxel, carboplatin and radiation in advanced head and neck cancer (Stage III and IV) induces high rate of complete pathologic response (CR) at the primary site and high rate of organ preservation. Proc. Am. Soc. Clin. Oncol., 16, p.391a, 1997.
- 25 29. Smith, R.E., Thornton, D.E., and Allen, J. A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck cancer correlative lab studies. Sem. Oncol., 22, 41, 1995.
- 30 30. Creaven, P., Rayhavan, C., Pendayala, D. et al. Phase 1 study of paclitaxel and carboplatin: Implications for trials in head and neck cancer. Sem Oncol., 22, 13, 1995.
- 35 31. McGuire, W., Rowinsky, E., Rosenshein, N., Grumbine, F., Ettinger, D., Armstrong, D., and Donehower, R. Taxol: A unique antineoplastic agent with significant

activity in advanced ovarian epithelial neoplasms. Am. J. Intern. Med., 11, 273, 1989.

5 32. Rowinsky, E., Donehower, R., Jones, R., and Tucker, R. Microtubule change and cytotoxicity in leukemia cell lines treated with Taxol. Cancer Res., 48: 4093, 1988.

10 33. Chuang, L., Lotzova, E., Leath, J., Cook, K., Munkanah, A., Morris, M., and Wharton, J. Alterations of lymphocyte microtubule assembly, cytotoxicity and activation by the anticancer drug Taxol. Cancer Res., 54, 1286, 1994.

15 34. Steren, A., Sevin, B., Perras, J., Angioli, R., Ngugen, H., Guerra, L., et al. Taxol sensitizes human ovarian cancer cells to radiation. Gynecol. Oncol., 48, 252, 1993.

20 35. Sweeney, E., Sakakura, C., Shirahama, T., Masamune, A., Ohta, H., Hakomori, S. and Igarashi, Y. Sphingosine and its methylated derivative N,N-dimethyl sphingosine (DMS) induce apoptosis in a variety of human cancer cell lines. Int. J. Cancer, 66, 358, 1996.

25 36. Dressler, K.A., Mathias, S. and Kolesnick, R. N. Tumor necrosis factor- α activates the sphingomyelin signal transduction pathway in a cell-free system. Science, 255, 1715, 1992.

30 37. Kim, M.Y. Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor α and gamma-interferon. Specific role in cell differentiation. J. Biol. Chem., 266, 484, 1991.

35 38. Gulbins, E., Bissonette, R., Mahboudi, A., Martin, S., Nishioka, W., Brunner, T., Baier, G., Baier-Bitterlich G., Lang F. et al. FAS-induced apoptosis

is mediated via a ceramide-initiated RAS signaling pathway. Immunity, 2, 341, 1995.

5 39. Kerr, J.F., Wyllie, A.H., and Currie, A.R. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br. J. Cancer, 26, 239, 1972.

10 40. Bursh, W., Kliene, L., and Tenniswood, M. The biochemistry of cell death by apoptosis. Biochem. Cell. Biol., 68, 1071, 1990.

15 41. Friesen C., Herr, I., Krammer, P H and Debatin K M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Medicine, 2, 574, 1996.

20 42. Villunger, A., Egle, A., Kos, M., Hartmann BL, Geley S, Kofler R and Grell R. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res., 57, 3331, 1997.

25 43. Eischen, C. M., Kottke, T. J., Martins L M, Basi, G. S., Tung J. S., Earnshaw, W. C., Liebson P J and Kaufmann S H. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood, 90, 935-43, 1997.

30

44. Fountzilas G., Athanssiadis, A., Samantas, E. et al. Paclitaxel and carboplatin in recurrent and metastatic head and neck cancer: A phase II study. Semin. Oncol. 24, S265-S267, 1997.

35

45. Hitt, R.,Hornedo, J., Colomer, R., et al.Study of escalating doses of paclitaxel plus cisplatin in patients

09287884-04099

with inoperable head and neck cancer. Semin. Oncol. 24, S258-S264, 1997.

- 5 46. Conley, B., Jacobs, M., Suntharalingam et al., A
pilot trial of paclitaxel, carboplatin and concurrent
radiotherapy for unresectable squamous cell carcinoma of
the head and neck. Semin. Oncol. 24, S278-S280, 1997.

10

090304 1403

4th Series of Experiments
In vivo Studies Tu135 Cells

5 Ceramide, a sphingomyelin metabolite, provides the "death
signal" for apoptosis in mammalian cells. Paclitaxel, an
active chemotherapeutic agent, blocks cells in the G2/M
phase of the cell cycle. It has been shown that
paclitaxel and ceramide have synergistic cytotoxic
effects on the leukemic T-cell line Jurkat (D. Myrick,
10 1999, in press). The interaction of paclitaxel and
ceramide in a variety of solid tumor cancer cell lines is
further explored herein to determine whether there is
similar synergism in inducing cytotoxicity and apoptosis.

15 **MATERIALS AND METHODS**

Neoplastic human cell lines included Prostate (LnCaP),
Colon (HT29), Pancreatic Cancer (RWP-2) and head and neck
squamous carcinoma (TU138) which were maintained in RPMI-
20 1640 containing 10% fetal bovine serum. C6-Ceramide
(Sigma Chemicals) initially dissolved in ethanol and
paclitaxel (Taxol) (Bristol-Myers, Squibb, Inc.) were
diluted in RPMI. Each neoplastic cell line at 25×10^3
was incubated at 37°C in the presence and absence of
25 Paclitaxel with varying concentrations of Ceramide and
were subjected to the MTT dye assay for surviving cell
fractions at 72 hrs.

30 **IN VIVO STUDIES**

TU138 cells were implanted subcutaneously in nude mice
Balb/c NU/NU which were treated beginning on day 4 with
thrice weekly injections of Paclitaxel 120 $\mu\text{g}/0.1\text{ml}$,
Ceramide, 500 μg in 0.2 ml, or the combination and
35 control vehicle, and were observed over 6 weeks.

RESULTS

Paclitaxel induced cytotoxicity in most tumor cell lines tested with an ID50 of 6.0-60.0 ng/ml. Ceramide was equally cytotoxic at calculated ID50 of approximately 30.0-40.0 μ g/ml. Combination of the two enhanced cellular cytotoxicity in a synergistic manner (as indicated by the 50% isobologram).

TABLE 2

%Growth Inhibition of Human Cancer Cell Lines by Paclitaxel (Taxol) and Ceramide Alone and in Combination

CELL LINE	PACLITAXEL (600 ng/ml)	CERAMIDE (25 μ g/nl)	PACLITAXEL (600 ng/ml)plus CERAMIDE (25 μ g/ml)
HT29	16%	61%	81%
Jurkat	55%	8%	78%
LnCap	13%	25%	66%
PC-3	16%	8%	51%
RWP-2	2%	6%	75%
TU138	10%	28%	66%

Tumor growth of TU138 was significantly inhibited by combination of Paclitaxel and Ceramide (Figs. 11 & 12)

DISCUSSION

Ceramide enhances Paclitaxel-mediated cytotoxicity in several tumor cell lines and augments the anti-tumor effect of paclitaxel on one of the lines (TU 138) in an in vivo nude mouse model. The mechanism is not yet defined but in part appears related to cell cycle switching by Paclitaxel (G2/M cell cycle block) although other considerations related to apoptosis are under study (bcl-2 and BAX system, changes in intracellular ceramide and Fas ligand mediated events).

Parameter	Unit	Value	Standard Error	t-Statistic	p-Value
Intercept		1.0000	0.0000	1.0000	0.0000
Age	Years	0.0000	0.0000	0.0000	0.0000
Gender		0.0000	0.0000	0.0000	0.0000
Marital Status		0.0000	0.0000	0.0000	0.0000
Education	Years	0.0000	0.0000	0.0000	0.0000
Income	Thousands of Dollars	0.0000	0.0000	0.0000	0.0000
Health		0.0000	0.0000	0.0000	0.0000
Smoking		0.0000	0.0000	0.0000	0.0000
Alcohol		0.0000	0.0000	0.0000	0.0000
Exercise		0.0000	0.0000	0.0000	0.0000
Stress		0.0000	0.0000	0.0000	0.0000
Depression		0.0000	0.0000	0.0000	0.0000
Loneliness		0.0000	0.0000	0.0000	0.0000
Life Satisfaction		0.0000	0.0000	0.0000	0.0000
Overall Health		0.0000	0.0000	0.0000	0.0000
Physical Health		0.0000	0.0000	0.0000	0.0000
Mental Health		0.0000	0.0000	0.0000	0.0000
Emotional Health		0.0000	0.0000	0.0000	0.0000
Social Health		0.0000	0.0000	0.0000	0.0000
Quality of Life		0.0000	0.0000	0.0000	0.0000
Life Expectancy	Years	0.0000	0.0000	0.0000	0.0000
Healthcare Costs	Thousands of Dollars	0.0000	0.0000	0.0000	0.0000
Disability		0.0000	0.0000	0.0000	0.0000
Chronic Illness		0.0000	0.0000	0.0000	0.0000
Acute Illness		0.0000	0.0000	0.0000	0.0000
Medication		0.0000	0.0000	0.0000	0.0000
Hospitalization		0.0000	0.0000	0.0000	0.0000
Long-term Care		0.0000	0.0000	0.0000	0.0000
End of Life		0.0000	0.0000	0.0000	0.0000
Overall Quality		0.0000	0.0000	0.0000	0.0000
Physical Quality		0.0000	0.0000	0.0000	0.0000
Mental Quality		0.0000	0.0000	0.0000	0.0000
Emotional Quality		0.0000	0.0000	0.0000	0.0000
Social Quality		0.0000	0.0000	0.0000	0.0000
Life Satisfaction		0.0000	0.0000	0.0000	0.0000
Overall Health		0.0000	0.0000	0.0000	0.0000
Physical Health		0.0000	0.0000	0.0000	0.0000
Mental Health		0.0000	0.0000	0.0000	0.0000
Emotional Health		0.0000	0.0000	0.0000	0.0000
Social Health		0.0000	0.0000	0.0000	0.0000
Quality of Life		0.0000	0.0000	0.0000	0.0000
Life Expectancy	Years	0.0000	0.0000	0.0000	0.0000
Healthcare Costs	Thousands of Dollars	0.0000	0.0000	0.0000	0.0000
Disability		0.0000	0.0000	0.0000	0.0000
Chronic Illness		0.0000	0.0000	0.0000	0.0000
Acute Illness		0.0000	0.0000	0.0000	0.0000
Medication		0.0000	0.0000	0.0000	0.0000
Hospitalization		0.0000	0.0000	0.0000	0.0000
Long-term Care		0.0000	0.0000	0.0000	0.0000
End of Life		0.0000	0.0000	0.0000	0.0000
Overall Quality		0.0000	0.0000	0.0000	0.0000
Physical Quality		0.0000	0.0000	0.0000	0.0000
Mental Quality		0.0000	0.0000	0.0000	0.0000
Emotional Quality		0.0000	0.0000	0.0000	0.0000
Social Quality		0.0000	0.0000	0.0000	0.0000
Life Satisfaction		0.0000	0.0000	0.0000	0.0000
Overall Health		0.0000	0.0000	0.0000	0.0000
Physical Health		0.0000	0.0000	0.0000	0.0000
Mental Health		0.0000	0.0000	0.000	

5

10

30

35

This innovative and explorative study uses the most lethal combination of two diverse agents, paclitaxel and a naturally occurring compound termed ceramide. Concurrently, the *in vivo* application of these two agents in an animal model utilizing human breast carcinoma cells is examined. This explorative method has evolved from the application of these two agents first, in *in vitro* studies of a variety of neoplastic cell lines including leukemic, prostate, pancreatic and squamous cell carcinoma and second, in an *in vivo* study of a squamous carcinoma cell line in nude mice.

15

30

35

Although significant progress has been made in the management of breast carcinoma, improved treatment strategies are urgently needed for both locally advanced and metastatic breast carcinoma. Paclitaxel is a new agent with important cytotoxic activity in a variety of tumor cells and has demonstrated radiation sensitizing ability in select tumor cell models. The role of paclitaxel in the treatment of breast carcinoma is beginning to be established although its cellular mechanisms of action are still being defined. It is critical, however, to design adjuvant, neo adjuvant therapy for the treatment of recurrent disease.

Tumor Cell Growth and Drug Selection

The most important feature of malignancies is the clonal origin of tumor cells and their retention of proliferative capacity (1). The principle of therapy with cytotoxic drugs relies on the selective inhibition/lysis of neoplastic cells and not the normal cells or tissues. The basis for most chemotherapeutic drug action is the inhibition of DNA, RNA and/or protein synthesis. Since the growth of tumors is usually described by Gompertzian kinetics (2, 3), the effectiveness of chemotherapeutic drugs is determined by tumor growth fraction, doubling time and size. Furthermore, the application of chemotherapy, as outlined by the Goldie-Coldman (4) model, suggests that cells will mutate to develop drug resistance based on the inverse relationship between cure and cell number and is independent of the neoplastic cell growth kinetics. This model provides the basis for (a) early initiation of treatment when tumor burden or fraction and the likelihood of drug resistance is small and (b) effective treatment utilizing a combination of drugs to lower side effects and toxicities to achieve maximal neoplastic cell kill.

5 The specific drug selection in a given protocol is usually based on the mechanism of action of the drug in question, its effects on the cell cycle, its toxicity and its effectiveness against a given tumor. Paclitaxel (Taxol) is another antineoplastic agent isolated from the *Taxus brevifolia*, more commonly known as the Western Yew (5). The proposed mechanism whereby paclitaxel induces cytotoxicity is the stabilization of polymerization of tubulin monomers and prevention of depolymerization. 10 This leads to the arrest of the paclitaxel responsive cells in the G₂-M phase of the cell cycle. In contrast to Vincristine which affects the assembly of microtubules, paclitaxel blocks the depolymerization of assembled microtubules (6), thereby causing arrest of 15 growing cells in the mitotic phase of the cell cycle. The formation of multidrug resistant phenotype with the overproduction of P-glycoprotein has been shown to be a consequence of paclitaxel exposure (7) suggesting the need for developing treatment strategies which minimize the development of resistance. Although a variety of 20 research projects and clinical trials have recently sought to determine the antineoplastic action of paclitaxel in relation to breast carcinomas, its direct cellular (cell cycle progression) and molecular effects are only beginning to be elucidated. 25

Breast Cancer: Paclitaxel in Clinical Therapy

30 Paclitaxel as a single agent (n=25, 250 mg/m², 24 hour infusion every 21 day interval) has been evaluated in clinical trials of recurrent breast cancer with a complete and partial response rates of 12% and 44% respectively (8). The dose related toxicity, however, was severe. Interestingly, in a therapeutic regimen of 35 paclitaxel with doxorubicin it was observed that patients had impairment in the elimination of doxorubicin if paclitaxel was administered first suggesting a need for drug sequencing studies in a combination protocol.

In Eastern Cooperative Oncology Group (ECOG) studies (9) the maximally tolerated doses of doxorubicin (60 mg/m²) and paclitaxel (175 mg/m²) are given as a 24 hour continuous infusion in different combinations over a period of 3 weeks. In a separate study of chemotherapy-naive metastatic breast cancer, a 3 hour infusion of paclitaxel (90 mg/m²) is followed by a 60 mg/m² cisplatin every 2 weeks (10). This protocol allows for an increase in the dose of paclitaxel up to 130 mg/m² without changing the cisplatin dose. While severe toxicity is observed, the results of this study demonstrate 25% complete and 69% partial response rates with an overall response rate of 94%. In another combination therapeutic protocol for recurrent breast carcinoma (n=40), paclitaxel (135 mg/m²) has been administered with cyclophosphamide (750 mg/m²) in various combinations with the following results (11): partial response: 4, no change: 18 and progressive disease: 18. While the efficacy of paclitaxel as a single agent is yet to be established, its combination with different agents has shown promising results in selected patients.

Breast Cancer: *In Vitro* and *In Vivo* Animal Studies with Paclitaxel

Many *in vitro* cellular studies and *in vivo* animal studies with human breast carcinoma cells have sought to examine the effect of various cytotoxic agents with paclitaxel. These cytotoxic agents include etoposide, vinorelbine, cis-platin, vinblastin and tamoxifen. The studies with etoposide in combination with paclitaxel demonstrated optimal effect on MCF-7, a breast carcinoma cell line to be dependent on the delivery schedule of the drugs in a sequential manner (12). Paclitaxel induced growth inhibition of MCF-7 in the presence of cis-platin demonstrated merely additive effects (13). Interestingly, while both vinorelbine and paclitaxel bind to distinct sites on tubulin with opposing effects on

microtubules they demonstrated synergistic effects on MCF-7 cell cytotoxicity when administered concurrently. Paclitaxel has been demonstrated to be efficacious on hormone refractory breast cancer cells (14), tumor cells with disruptions in p53 (15) or cells with overexpression of HER-2 gene (16).

Additionally, many recent studies have examined (a) the differential effects of drugs or agents on cell cycle progressions. In these studies, panel of cells including breast carcinoma were combined with adenovirus-mediated gene therapy (G_0 - G_1 blocker) in combination with either simultaneous or post paclitaxel (G_2 -M blocker) treatment (17). While no interactive antagonistic activity was observed, the combination had either synergistic or additive effect. Interestingly, the relative concentration of each agent determined the dominant response in terms of cell cycle progression and cell death; (b) the activation of molecular pathways leading to apoptosis with the help of radioimmunotherapy. These studies demonstrated that timing and sequencing of paclitaxel and 90Y-DOTA-peptide-ChL6 antibody (90Y-ChL6) is critical in combined modality for maximal effectiveness in human breast carcinoma cells (HBT 3477) in nude mice (18); and (c) the inhibition of angiogenesis by paclitaxel in addition to Vincristin, colchicin and 2-methoxyestradiol (19).

It is clear the review of literature on paclitaxel presented here indicates the following: (a) paclitaxel in combination with other drugs is more effective than as a single agent, (b) the definition of the mode of addition of different agents in a combination protocol is essential to achieve maximum therapeutic benefit, (c) the mechanism of action for the induction of apoptosis may be dependent on the concentration of available paclitaxel and (d) the sequential addition of low dose over an extended period of time may be more effective than one

big bolus of paclitaxel. These studies also suggest that the discovery of a new agent, ceramide, that complements and amplifies the action of paclitaxel is important consideration in therapeutic strategies to eventually eliminate the abnormal growth of tumor cells.

Ceramide and Breast Cancer

Sphingolipids have been shown to be biologically active and have numerous regulatory effects on cell function including cell growth and differentiation. A number of inducers of sphingomyelin hydrolysis causing concomittant elevation of intracellular ceramide have been identified. These include $\text{TNF}\alpha$, endotoxins, interferon alpha, IL-1, Fas ligand, chemotherapeutic agents, heat and ionizing radiation (20). Ceramide synthesis *de novo* has been implicated in lethal responses to several chemotherapeutic agents such as anthracyclins (21) and ara-C (22). Many recent studies have examined the effect of exogeneous ceramide on the induction of apoptosis in a variety of tumor cells. Ceramide has been shown in such cases to cause cell cycle arrest in several cell lines as well as apoptosis, cell senescence and terminal differentiation (23-26). The role of ceramide induced cytotoxicity in breast carcinoma is reported by many laboratories. These studies have examined the effect of cell permeable C6-ceramide to cause apoptosis in $\text{TNF}\alpha$ resistant MCF-7 cell line and increase in intracellular ceramide as a consequence of sphingomyelin hydrolysis due to the addition of $\text{TNF}\alpha$ on sensitive MCF-7 cells (27). Cell permeable C2-ceramide was shown to cause apoptosis in another human breast cancer cell line, Hs578T which was enhanced by the addition of insulin-like growth factor binding protein-3 (28). Interestingly, suramin-induced cell death in human breast, prostate and neuron like cell lines have been shown to have elevated levels of intracellular ceramide prior to apoptosis (29).

Mechanisms of Action in Paclitaxel or Ceramide Induced Apoptosis

There are many proposed mechanisms of action for paclitaxel induced cell death. These include the phosphorylation of bcl-2 (30) in prostate cancer cells, transient activation of JNK pathway (31) in leukemic cells and sensitization and activation of FasR on cell surface (1st series of experiments). Similarly, multitudes of apoptotic pathways leading to the activation of bcl-2/BAX, JNK/SAPK, FasR/FasL, etc. have been proposed as a consequence to ceramide addition in a variety of cellular models (32). It should be pointed out that no studies have recorded the combined effects of paclitaxel and ceramide on many of these proposed pathways.

Preliminary Studies: Paclitaxel and Ceramide Action In Vitro

The present studies (1st series of experiments) with a human leukemic T-cell line, Jurkat have demonstrated that the addition of C6-ceramide enhanced paclitaxel-mediated apoptosis in a synergistic manner. These studies also established that the apoptotic population of Jurkat cells was from either S or G₂-M phase of the cell cycle. In these studies, the apoptosis was measured by Wright stain, TUNEL assay and flow cytometric evaluations.

Paclitaxel and cell permeable C6-ceramide mediated synergy for observed apoptosis was also evident in a squamous carcinoma cell line, TU-138. The evaluation of apoptosis was carried out by TUNEL assay. Flow cytometric studies confirmed the earlier observations with Jurkat cells that the loss of cells to apoptosis was derived from either S or G₂-M phase of the cell cycle. The synergistic response of paclitaxel and ceramide was confirmed by the isobologram analysis and its

significance was established by student's T-test.

It was also observed that paclitaxel and C6-ceramide induced synergistic growth inhibition in a variety of tumor cell lines including prostate (hormone sensitive LnCaP and hormone refractory PC-3), pancreatic (RWP-2) and breast (MCF-7) carcinoma cell lines.

In addition, the studies with breast carcinoma cell line, MCF-7 have suggested that the concentration of paclitaxel added at the onset of cultures is critical to the progression of cell cycle. At lower than ID_{50} paclitaxel concentrations (0.6 - 6.0 ng/ml), it was more efficacious, blocking greater than 55% of cells in to G_2/M phase of the cell cycle. Interestingly, at higher than ID_{50} concentrations, paclitaxel clearly affected the movement of cells from G_1 phase of the cell cycle reducing the number of cells into G_2/M phase to 38%.

Preliminary Studies: Paclitaxel and Ceramide Action In Vivo

To corroborate the in vitro findings of synergistic action of paclitaxel and ceramide, TU-138 cells were planted subcutaneously in nude mice at day 0. The treatment with paclitaxel ($120\mu\text{g}$ in 0.1 mL) and ceramide ($500\mu\text{g}$ in 0.2 mL) was begun on day 4 with thrice weekly injections administered subcutaneously near the site of the tumor implantation on squamous cell carcinoma cell line TU-138 for a period of 5 weeks. The following control groups were run: vehicle only, paclitaxel alone and ceramide alone. The size of the tumor was measured once a week and continued for 6 weeks (Figure 11). All groups of mice were sacrificed on day 45 and the excised tumor was weighed (Figure 12). The data presented are preliminary, but nevertheless indicate that TU-138 cell-tumor grew aggressively in control and paclitaxel treated mice almost equally. The group with only ceramide

injections demonstrate a slight decrease in tumor size at week 5. The group with both paclitaxel and ceramide showed a decline of 79% in tumor size in comparison to control group.

5

The significant reduction (88% in paclitaxel + ceramide in contrast to control only) in tumor weight corroborated these findings as shown in Figure 12. Interestingly, the ceramide only group did demonstrate a substantial reduction in tumor weight. The data is currently being evaluated statistically. The excised tumors are currently being subjected for histopathological studies to determine tumor cell morphology and cellular apoptosis.

10

The existing protocols of combination chemotherapy utilizing paclitaxel are only partially effective. Therapeutic strategies that involve ceramide *in vivo* in breast carcinoma have not been reported yet.

15

Paclitaxel induces transient growth arrest of breast cancer cells into the G₂-M phase of the cell cycle. A simultaneous or progressive addition of ceramide, a G₀-G₁ blocker, will result in greater apoptosis either by targeting those cells that escaped paclitaxel effects or by activating complementary apoptotic pathways. This will result in increased effects of paclitaxel at concentrations lower than those currently employed in clinical protocols.

20

25

30 Technical Objectives

35

The long-term objectives of this study include determination of the most efficacious clinical and therapeutic basis of paclitaxel effects on breast cancer cells. These studies focus on (a) examinations of the kinetics of the combined effects of paclitaxel and ceramide in cell growth inhibition and lysis *in vitro* and (b) corroboration of the *in vitro* studies in an *in vivo*

nude mouse model utilizing breast carcinoma cell line. The specific aims of the studies are set forth below.

5 Evaluation of paclitaxel and ceramide in a combination
therapy utilizing a nude mouse model bearing human breast
tumor: Paclitaxel as a single agent has been shown to
negatively modulate the growth of breast carcinoma in the
clinic and also in the laboratory studies. Cell-permeable
10 exogenously added ceramide has also been shown to induce
apoptosis in a variety of cancer cell lines in vitro
including breast carcinoma. The studies combine these two
agents with diverse mechanism of actions to enhance the
cytotoxic effects of each other. This innovative approach
is based on the rationale that unaffected cells by one
15 agent will be targeted by the other agent as a direct
effect. At the same time these two agents will amplify
the converging point(s) in an otherwise enhanced pathway
toward apoptosis resulting in a synergistic interaction.
Such synergistic action has been observed with paclitaxel
20 and ceramide in a squamous carcinoma cells grown *in vivo*
in nude mice in the laboratory.

25 Establish the necessary and sufficient conditions for the
growth inhibition and cellular cytotoxicity effects of
paclitaxel and ceramide when added simultaneously or in
sequence followed by the determination of apoptosis of
the cells of breast carcinoma: The studies focus on the
kinetics of the addition of paclitaxel and/or ceramide
and their effect on cell cycle progression of breast
30 cancer cells. The studies also investigate apoptosis by
a variety of available methods.

Experimental Design and Methods:

Breast Cancer and Drug Delivery

35 Combination drug delivery is an essential component of
the inhibition of tumor cell telesis (programmed cell
growth) and eventual apoptosis (programmed cell death).

5 Cancer treatment with paclitaxel has been coupled with
different therapeutic modalities which include radiation
and/or chemotherapeutic agents as described earlier. For
in vitro studies many different breast cancer cell lines
have been utilized to establish the effects of
combination of drugs. Nude mouse model with implanted
human breast cancer cells have been utilized in a number
of studies. In these studies drugs have been delivered
in a variety of ways including intraperitoneal,
10 intravenous or subcutaneous injections. The vehicle for
drug delivery is also an essential component as it
affects drug stability, toxicity and pharmacokinetics.
Paclitaxel has been delivered in cremophore or liposomes
in many animal studies (33). Sphingolipids have been
15 delivered in vivo via liposome preparations (34).

These preliminary studies with squamous cell carcinoma in
nude mice (Balb/c strain, Taconic Farms, NY) paclitaxel
and ceramide were delivered in very small amounts in
cremophore and alcohol respectively. In the first phase
of these studies the paclitaxel is delivered in
cremophore and C6-ceramide in alcohol solution diluted
with culture medium. These studies include all
appropriate vehicle controls (medium, alcohol and/or
25 cremophore alone) in appropriate concentrations. The
experimental and control group also includes paclitaxel,
ceramide and a combination of paclitaxel and ceramide.
These agents are delivered on day 4 after the
implantation of MCF-7 (breast cancer cell line) cells in
30 nude mice. Appropriate drugs are injected subcutaneously
three times weekly and the growth of tumor is followed
for approximately 6-8 weeks. This time period is derived
from preliminary studies on head and neck cancer cells in
nude mice. These studies are initially done in various
groups (including controls all done at the same time)
35 with 5 mice each. This set of studies is repeated at
least 3 times and the data subjected to statistical
analysis to obtain the confidence limits.

As indicated earlier liposome preparations of paclitaxel have been as efficacious or better than standard preparations in cremophore. Also, liposome preparations of sphingolipids have been shown to have greater effect because of its stability than free sphingolipids (34). Therefore, C6-ceramide may be prepared in liposomes as indicated in the methods section. The experimental design with liposomal formulations includes appropriate controls including liposome preparations without ceramide and/or paclitaxel. Liposome formulations may be administered intraperitoneally as well.

A set of *in vitro* experiments is performed to assess the effect of liposome formulations on MCF-7 with appropriate controls. In these experiments, cells are subjected simultaneously or sequentially with paclitaxel and ceramide. If results indicate simultaneous treatment to be better than sequential treatment then a single liposome formulation with paclitaxel and ceramide combined will be prepared and tested again with its appropriate controls as indicated earlier. A minimum of 15 nude mice in three separate sets of experiments are tested in experimental protocols. Based on studies with squamous carcinoma cells that a sum total of these experiments provide enough samples to be tested for significance by statistical analysis.

For the evaluation of the combined effects of paclitaxel and ceramide *in vivo* the following measurements are performed: (1) tumor growth in millimeters, (2) excised tumor weight at the completion of experiments, (3) histopathology of excised tumors and (4) the identification of apoptotic cells using TUNEL method. The measurement of tumor growth and weight is a routine procedure and is performed by a trained animal technician. The identification of apoptotic cells by TUNEL assay is also a routine procedure in the laboratory

5

10

15

20

25

30

References for 5th Series of Experiments

1. Ford, R., A. Goodacre, S. Mehta, and F. Cabanilas. Establishment and characterization of human neoplastic B-cell lines. Blood. 75: 1311, 1990.
2. Mendelsohn, M. The growth fraction: A new concept applied to tumors. Science. 132: 1496, 1960.
3. Devita, V., C. Denham, and S. Perry. Relationship of normal CDF1 mouse leucocyte kinetics to growth characteristics of leukemia L1210. Cancer Res. 29: 1067-1071, 1969.
4. Goldi, J. and A. Coldman. A mathematic model for relating the drug sensitivity of tumors to the spontaneous mutation rate. Cancer Treat. Rep. 63: 1727-1733, 1979.
5. Wani, M., H. Taylor, M. Wall, P. Coggan, and A. McPhail. Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. Am. Chem. Soc. 93: 2325-2337, 1971.
6. Owellen, R., C. Hartke, R. Dickinson, and F. Hains. Inhibition of tubulin microtubulin polymerization by drugs of the Vinca alkaloid class. Cancer Res. 36: 1499-1502, 1976.
7. Howitz, S.B., D. Cohen, S. Rao, I. Rignel, H. Shen, and C.H. Yang. Taxol: Mechanisms of Action and Resistance. J. Natl. Cancer Inst. (Monographs). 15: 55-61, 1993.
8. Buzdar, A., F. Holmes, and G. Hortobagyi. Paclitaxel in the treatment of metastatic breast cancer. M.D. Anderson Cancer Center experience in the Emerging Role in Pacitaxel in Cancer Chemotherapy. Sem Oncol. 22(3) Suppl

6: 101-104, 1995.

9. Sledge, G., N. Robert, J. Sparano, M. Cogleigh, L. Goldstein, D. Neuberg, E. Rowinsky, C. Baughman and W. McCaskill-Stevens. Eastern Cooperative Oncology Group Studies of Paclitaxel and Doxorubicin in Advanced Breast Cancer in the Emerging Role of Paclitaxel in Cancer Chemotherapy. Sem Oncol. 22(3) Suppl 6: 105-108, 1995.

10. O'Reilly, S. And K. Gelmon. Biweekly paclitaxel and cis-platinum: A Phase I/II study in the First-Line treatment of metastatic breast cancer in the Emerging Role of Paclitaxel in Cancer Chemotherapy. Sem Oncol. 22(3) Suppl 6: 109-111, 1995.

11. Sessa, C., O. Pagani, G. Parma, A. Goldhirsch, and F. Cavalli. Dose-Finding Study of Paclitaxel and Cyclophosphamide in Patients with Advanced Breast Cancer in the Emergin Role of Paclitaxel in Cancer Chemotherapy. Sem Oncol. 22(3) Suppl 6: 112-117, 1995.

12. Perez, E.A. and C.A. Buckwalter. Sequence-dependent cytotoicity of etoposide and paclitaxel in human breast and lung cancer cell lines. Cancer Chemother. Pharmacol. 41(6): 448-452, 1998.

13. Liebmann, J.E., J. Fisher, D. Teague and J.A. Cook. Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells. Oncol. Res. 6(1): 25-31, 1994.

14. Kurbacher, C.M., U. Wagner, B. Kolster, P.E. Andreotti, D. Krebs, and H.W. Bruckner. Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin and cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett. Jun 5, 103(2): 183-189, 1996.

15. Fan, S., B. Cherney, W. Reinhold, K. Rucker, and P.M. O'Connor. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vinicristine treatment. Clin. Cancer Res. Apr. 4(4):1047-1054, 1998.

16. Baselga, J., A.D. Seidman, P.P. Rosen and L. Norton. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncol., Mar 11 (3 suppl 2), 43, 1997.

17. Nielsen, L.L., P. Lipari, J. Dell, M. Gurnani and G. Hajian. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate and breast cancer. Clin. Cancer Res., 4, 835-846, 1998.

18. DeNardo, S., L. Kroger, L. Lamborn, L. Miers, R. O'Donnell, D. Kukis, C. Richman and G. DeNardo. Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma. Cancer, 80, 2583-2590, 1997.

19. Klaubner, N., S. Parangi, E. Flynn, E. Hammel and R. D'Amato. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2- methoxyestradiol and taxol. Cancer Res. 57, 81-86, 1997.

20. Hannun, Y. The sphingomyelin cycle and the second messenger function of ceramide. J Biol Chem 269, 3125, 1994.

21. Bose, R., M. Verheji, A. Haimovits-Friedman, K. Scotto, Z. Fuks, and R. Kolesnick. Ceramide synthase mediates daunorubicin-induced apoptosis: and alternative mechanism for generating death signals. Cell, 82: 405-414, 1995.

22. Strum, J.C., G.W. Small, S.B. Daiug, and L.W. Daniel.
1-B-D arabinofuranosylcytosine stimulates ceramid and
diglyceride formation in HL-60 cells. J. Biol. Chem.
269, 15493, 1994.

23. Jayadev, S., B. Liu, A.E. Bielawska, J.Y. Lee, F.
Nazaire, M. Pushkareva, L.M. Obeid, and Y.A. Hannun.
Role for ceramide in cell cycle arrest. J. Biol. Chem.,
270, 2047, 1995.

24. Bielawska, A., C.M. Linardic, and Y.A. Hannun.
Modulation of cell growth and differentiation by
ceramide. FEBS Lett, 307, 211, 1992.

25. Obeid, L.M. and Y.A. Hannun. Ceramide: a stress
signal and mediator of growth suppression and apoptosis.
J. Cell Biochem., 58, 191, 1995.

26. Jarvis, W.D., R.N. Kolesnick, F.A. Fornari, R.S. Tra-
ylor, D.A. Gewirtz, and S. Grant. Induction of apoptotic
DNA damage and cell death by activation of the sphin-
gomyelin pathway. Proc. Natl. Acad. Sci USA 91, 73, 1995.

27. Cai, Z., A. Bettaieb, N.E. Mabdani, L.G. Legres, R.
Stancou, J. Masliah, and S. Chouaib. Alteration of the
sphingomyelin/cramide pathway is associated with
resistance of human breast carcinoma MCF7 cells to tumor
necrosis factor-alpha-mediated cytotoxicity. J. Biol.
Chem., 272(11):6918-6926, 1997.

28. Gill, Z.P., C.M. Perks, P.V. Newcomb, and J.M Holly.
Insulin-like growth factor-binding protein (IGFBP-3)
predisposes breast cancer cells to programmed cell death
in a non-IGF-dependent manner. J. Biol. Chem.,
272(41):25602-25607, 1997.

29. Gill, J.S. and A.J. Windebank. Role of ceramide in
suramin-induced cancer cell death. Cancer Lett., 119(2):

169-176, 1997.

30. Halдар, S., J. Chintapalli and C. Croce. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. *Cancer Res.*, 56, 1253, 1996.

31. Amato, S., J. Swart, M. Berg, H. Wanebo, S. Mehta and T. Chiles. Transient stimulation of the c-Jun-NH2-terminal kinase/activator protein 1 pathway and inhibition of extracellular signal-regulated kinases are early effects in paclitaxel-mediated apoptosis in human B lymphoblasts. *Cancer Res.*, 58, 241, 1998.

32. Haimovitz-Friedman, A., R. Kolesnick and Z. Fuks. Ceramide signaling in apoptosis. *Br. Med. Bull*, 53, 539, 1997.

33. Cabanes, A., K. Briggs, P. Gokhale, J. Treat and A. Rahman. Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel. *Intl. J. Oncol.*, 12, 1035, 1998.

34. Shirabama, T., E. Sweeney, C. Sakakura, A. Singhal, K. Nishiyama, S. Akiyama, S. Hakamori and Y. Igarashi. In vitro and in vivo induction of apoptosis by sphingosine and N, N-dimethylsphingosine in human epidermoid carcinoma KB-3-1 and its multidrug-resistant cells. *Clin. Cancer Res*, 3, 257-264, 1997.

What is claimed is:

1. A method for increasing apoptosis in tumor cells comprising contacting the tumor cells with:
 - a) an effective amount of at least one antitumor chemotherapeutic agent and
 - b) an effective amount of a ceramide, sequentially or concomitantly, wherein the apoptosis induced by the combination of the antitumor chemotherapeutic agent and the ceramide is greater than the apoptosis induced by contact of the tumor cells with either the antitumor chemotherapeutic agent alone or the ceramide alone, thereby increasing apoptosis in tumor cells.
2. A method of decreasing a size of a tumor comprising contacting the tumor with:
 - a) an effective amount of at least one antitumor chemotherapeutic agent and
 - b) an effective amount of a ceramide, sequentially or concomitantly, wherein the induced decrease in size of the tumor by the combination of the antitumor chemotherapeutic agent and the ceramide is greater than the decrease in size of a tumor after contacting the tumor with either the antitumor chemotherapeutic agent alone or the ceramide alone, thereby decreasing the size of the tumor.
3. The method according to either claim 1 or 2, wherein the tumor cells are or the tumor is composed of cancer cells selected from the group consisting of leukemic cells, prostate cancer cells, pancreatic cancer cells and squamous cell carcinoma cells, breast carcinoma cells, melanoma cells, basal cell carcinoma cells, neuroblastoma cells, glioblastoma multiforme cells, myeloid leukemic cells, colon carcinoma cells, endometrial

carcinoma cells, lung carcinoma cells, ovarian carcinoma cells, cervical carcinoma cells, osteosarcoma cells and lymphoma cells.

- 5 4. A method according to either claim 1 or 2, wherein the tumor cells or the tumor are contacted first with at least one antitumor chemotherapeutic agent and subsequently contacted with the ceramide.
- 10 5. A method according to either claim 1 or 2 wherein the tumor cells or the tumor are present in a subject.
- 15 6. The method according to either claim 1 or 2, wherein the ceramide is selected from a C2-ceramide, C6-ceramide, C8-ceramide and a higher order ceramide.
- 20 7. The method according to either claim 1 or 2, wherein the antitumor chemotherapeutic agent is selected from the group consisting of paclitaxel, doxorubicin, cis-platin, cyclophosphamide, etoposide, vinorelbine, vinblastin, tamoxifen, colchinin, and 2-methoxyestradiol.
- 25 8. The method according to either claim 1 or 2, wherein the contacting with the antitumor chemotherapeutic agent is effected by cremophore delivery or liposome-mediated delivery and the contacting with the ceramide is effected by cremophore delivery, alcohol-mediated delivery or liposome-mediated delivery.
- 30 9. The method according to either claim 1 or 2, wherein the contacting with the antitumor chemotherapeutic agent and with the ceramide is effected by an administration route selected from the group consisting of intravenous,
- 35

intraperitoneal, intrathecal, intralymphatical, intramuscular, intralesional, parenteral, epidural, or subcutaneous administration; by infusion, by aerosol delivery; or by topical, oral, nasal, anal, ocular or otic delivery.

10. A pharmaceutical composition comprising at least one antitumor chemotherapeutic agent in an amount effective to induce apoptosis of tumor cells and a ceramide in an amount effective to induce apoptosis of tumor cells and a pharmaceutically acceptable carrier.
11. A method for treating cancer in a subject comprising administering to the subject an effective amount of at least one antitumor chemotherapeutic agent and an effective amount of at least one ceramide, sequentially or concomitantly.
12. The method according to claim 11, wherein at least one antitumor chemotherapeutic agent and subsequently at least one ceramide is administered to the subject.
13. The method according to claim 11, wherein at least one ceramide and subsequently at least one antitumor chemotherapeutic agent is administered to the subject.
14. A method according to claim 11, wherein the antitumor chemotherapeutic agent is paclitaxel and the ceramide is C6-ceramide.
15. A method according to claim 11, wherein the ceramide is a C2-ceramide, C6-ceramide, C8-ceramide or a higher order ceramide.

COMBINATIONS OF C6 CERAMIDE AND CHEMOTHERAPEUTIC AGENTS
FOR INDUCING CELL DEATH AND USES THEREOF IN TREATING
CANCER

5 Abstract of the Disclosure

10 This invention provides a method for increasing apoptosis
in tumor cells and a method of decreasing a size of a
tumor, said methods comprising contacting the tumor cells
with: a) an effective amount of at least one antitumor
chemotherapeutic agent and b) an effective amount of a
ceramide, sequentially or concomitantly, wherein the
apoptosis induced by the combination of the antitumor
chemotherapeutic agent and the ceramide is greater than
15 the apoptosis induced by contact of the tumor cells with
either the antitumor chemotherapeutic agent alone or the
ceramide alone. This invention also provides a method of
treating cancer in a subject which comprises a method
according to either of the above-described methods. This
20 invention provides a method for treating cancer in a
subject comprising administering to the subject an
effective amount of at least one antitumor chemo-
therapeutic agent and an effective amount of at least one
ceramide, sequentially or concomitantly. This invention
25 provides a pharmaceutical composition comprising at least
one antitumor chemotherapeutic agent in an amount
effective to induce apoptosis of tumor cells and at least
one ceramide in an amount effective to induce apoptosis
of tumor cells and a pharmaceutically acceptable carrier.

30

35




FIG. 2
Effect of Serum on Taxol and Ceramide
Induced Jurkat Cell Growth Inhibition




FIG. 3B





FIG. 3D





FIG. 3A







FIG. 3C



4/17

FIG. 3F




FIG. 3E




FIG. 4A

Untreated



FIG. 4B

+25 μ g/ml Ceramide




FIG. 4C

+0.6 ng/ml Paclitaxel




FIG. 4D

+6.0 ng/ml Paclitaxel




FIG. 4E

0.6 ng/ml Paclitaxel
+
25 μ g/ml Ceramide



FIG. 4F

6.0 ng/ml Paclitaxel
+
25 μ g/ml Ceramide



Taxol and Ceramide Induction of Apoptosis in Jurkat Cells

FIG. 5A (24 Hours)




FIG. 5B




FIG. 5C




FIG. 5D




FIG. 5E (48 Hours)




FIG. 5F




FIG. 5G






FIG. 5H



9/17

FIG. 6A

Effect of Paclitaxel on Tu138 Cell Survival



10/17

FIG. 6B

Effect of Ceramide on Tu138 Cell Survival





FIG. 7**Time Kinetics of Combined Additions of Paclitaxel and Ceramide**

FIG. 8

**50% Isobologram Analysis of Paclitaxel and
Ceramide Exposed Tu138 cell survival**





FIG. 9A


G₀-G₁: 59.1%

S: 33.5%

G₂-M: 7.4%

Control - No Additions (24 hours)

FIG. 9B


G₀-G₁: 56.7%

S: 26.8%

G₂-M: 16.5%

Ceramide 25 µg/ml (24 hours)

FIG. 9C


G₀-G₁: 9.5%

S: 28.7%

G₂-M: 61.8%

Paclitaxel 600 ng/ml (24 hours)

FIG. 9D


G₀-G₁: 17.2%

S: 37.2%

G₂-M: 45.6%Ceramide 25 µg/ml (24 hours)
+ Paclitaxel 600 ng/ml

14/17


FIG. 9E



G₀-G₁: 53.9%
S: 40.2%
G₂-M: 6.0%

Control - No additions (48 hours)


FIG. 9F



G₀-G₁: 54.9%
S: 39.6%
G₂-M: 5.5%

Ceramide 25 µg/ml (48 hours)


FIG. 9G



G₀-G₁: 16.7%
S: 25.2%
G₂-M: 58.2%

Paclitaxel 600 ng/ml (48 hours)

FIG. 9H



G₀-G₁: 71.6%
S: <1%
G₂-M: 28.4%

Ceramide 25 µg/ml (48 hours)
+ Paclitaxel 600 ng/ml

Time Kinetics Of The Induction Of Apoptosis By Paclitaxel And Ceramide Acting In Combination.


FIG. 10A

FIG. 10B


FIG. 10C

FIG. 10D


24 Hours Of Taxol And/Or Ceramide Exposure.




Control - no additions
Apoptosis: 8.7%



Ceramide (25 µg/ml)
Apoptosis: 9.7%



Paclitaxel (600 ng/ml)
Apoptosis: 18.35%



Ceramide 25 µg/ml
+ Paclitaxel 600 ng/ml
Apoptosis: 53.7%


FIG. 10E

FIG. 10F


FIG. 10G

FIG. 10H


48 Hours Of Taxol And/Or Ceramide Exposure.




Control - no additions
Apoptosis: 7.8%



Ceramide (25 µg/ml)
Apoptosis: 13.6%



Paclitaxel (600 ng/ml)
Apoptosis: 54.7%



Ceramide (25 µg/ml)
+ Paclitaxel 600 ng/ml
Apoptosis: 84.9%

FIG. 11 Growth of Human Squamous Carcinoma Cells in Nude Mice




FIG. 12 Excised Tumor Weights

